2a5u › Citations

Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.

Camps M, Rückle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Françon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte PA, Hirsch E, Wymann MP, Cirillo R, Schwarz MK, Rommel C
Nat Med 11 936-43 (2005)
Cited: 476 times
EuropePMC logo PMID: 16127437

Abstract

Phosphoinositide 3-kinases (PI3K) have long been considered promising drug targets for the treatment of inflammatory and autoimmune disorders as well as cancer and cardiovascular diseases. But the lack of specificity, isoform selectivity and poor biopharmaceutical profile of PI3K inhibitors have so far hampered rigorous disease-relevant target validation. Here we describe the identification and development of specific, selective and orally active small-molecule inhibitors of PI3Kgamma (encoded by Pik3cg). We show that Pik3cg(-/-) mice are largely protected in mouse models of rheumatoid arthritis; this protection correlates with defective neutrophil migration, further validating PI3Kgamma as a therapeutic target. We also describe that oral treatment with a PI3Kgamma inhibitor suppresses the progression of joint inflammation and damage in two distinct mouse models of rheumatoid arthritis, reproducing the protective effects shown by Pik3cg(-/-) mice. Our results identify selective PI3Kgamma inhibitors as potential therapeutic molecules for the treatment of chronic inflammatory disorders such as rheumatoid arthritis.

Reviews - 2a5u mentioned but not cited (3)

  1. Copaifera of the Neotropics: A Review of the Phytochemistry and Pharmacology. da Trindade R, da Silva JK, Setzer WN. Int J Mol Sci 19 E1511 (2018)
  2. Advances in chemical proteomic evaluation of lipid kinases-DAG kinases as a case study. Ware TB, Hsu KL. Curr Opin Chem Biol 65 101-108 (2021)
  3. Target-Based Small Molecule Drug Discovery for Colorectal Cancer: A Review of Molecular Pathways and In Silico Studies. Moshawih S, Lim AF, Ardianto C, Goh KW, Kifli N, Goh HP, Jarrar Q, Ming LC. Biomolecules 12 878 (2022)

Articles - 2a5u mentioned but not cited (8)

  1. Flavonoids inhibit cell proliferation and induce apoptosis and autophagy through downregulation of PI3Kγ mediated PI3K/AKT/mTOR/p70S6K/ULK signaling pathway in human breast cancer cells. Zhang HW, Hu JJ, Fu RQ, Liu X, Zhang YH, Li J, Liu L, Li YN, Deng Q, Luo QS, Ouyang Q, Gao N. Sci Rep 8 11255 (2018)
  2. Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach. Zhao Z, Xie L, Xie L, Bourne PE. J Med Chem 59 4326-4341 (2016)
  3. Identification of Druggable Kinase Target Conformations Using Markov Model Metastable States Analysis of apo-Abl. Paul F, Meng Y, Roux B. J Chem Theory Comput 16 1896-1912 (2020)
  4. Thiazolidinedione-based PI3Kα inhibitors: an analysis of biochemical and virtual screening methods. Pinson JA, Schmidt-Kittler O, Zhu J, Jennings IG, Kinzler KW, Vogelstein B, Chalmers DK, Thompson PE. ChemMedChem 6 514-522 (2011)
  5. Identification of Antitumor Active Constituents in Polygonatum sibiricum Flower by UPLC-Q-TOF-MSE and Network Pharmacology. Huang ZZ, Du X, Ma CD, Zhang RR, Gong WL, Liu F. ACS Omega 5 29755-29764 (2020)
  6. Understanding the polypharmacological anticancer effects of Xiao Chai Hu Tang via a computational pharmacological model. Zheng CS, Wu YS, Bao HJ, Xu XJ, Chen XQ, Ye HZ, Wu GW, Xu HF, Li XH, Chen JS, Liu XX. Exp Ther Med 7 1777-1783 (2014)
  7. Discovery of novel selective PI3Kγ inhibitors through combining machine learning-based virtual screening with multiple protein structures and bio-evaluation. Zhu J, Li K, Xu L, Cai Y, Chen Y, Zhao X, Li H, Huang G, Jin J. J Adv Res 36 1-13 (2022)
  8. Novel Mechanism for an Old Drug: Phenazopyridine is a Kinase Inhibitor Affecting Autophagy and Cellular Differentiation. Preynat-Seauve O, Nguyen EB, Westermaier Y, Héritier M, Tardy S, Cambet Y, Feyeux M, Caillon A, Scapozza L, Krause KH. Front Pharmacol 12 664608 (2021)


Reviews citing this publication (97)

  1. Phosphoinositides: tiny lipids with giant impact on cell regulation. Balla T. Physiol Rev 93 1019-1137 (2013)
  2. Lipid signalling in disease. Wymann MP, Schneiter R. Nat Rev Mol Cell Biol 9 162-176 (2008)
  3. Neutrophil function in inflammation and inflammatory diseases. Wright HL, Moots RJ, Bucknall RC, Edwards SW. Rheumatology (Oxford) 49 1618-1631 (2010)
  4. Chemokines and their receptors: drug targets in immunity and inflammation. Viola A, Luster AD. Annu Rev Pharmacol Toxicol 48 171-197 (2008)
  5. Interstitial leukocyte migration and immune function. Friedl P, Weigelin B. Nat Immunol 9 960-969 (2008)
  6. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Rommel C, Camps M, Ji H. Nat Rev Immunol 7 191-201 (2007)
  7. Insulin resistance and atherosclerosis. Semenkovich CF. J Clin Invest 116 1813-1822 (2006)
  8. Signaling by the phosphoinositide 3-kinase family in immune cells. Okkenhaug K. Annu Rev Immunol 31 675-704 (2013)
  9. G protein βγ subunits: central mediators of G protein-coupled receptor signaling. Smrcka AV. Cell Mol Life Sci 65 2191-2214 (2008)
  10. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, Drexler H, Filippatos G, Felix SB, Gullestad L, Hilfiker-Kleiner D, Janssens S, Latini R, Neubauer G, Paulus WJ, Pieske B, Ponikowski P, Schroen B, Schultheiss HP, Tschöpe C, Van Bilsen M, Zannad F, McMurray J, Shah AM. Eur J Heart Fail 11 119-129 (2009)
  11. Update on glucocorticoid action and resistance. Ito K, Chung KF, Adcock IM. J Allergy Clin Immunol 117 522-543 (2006)
  12. Neutrophils as emerging therapeutic targets. Németh T, Sperandio M, Mócsai A. Nat Rev Drug Discov 19 253-275 (2020)
  13. PI3Kgamma inhibition: towards an 'aspirin of the 21st century'? Rückle T, Schwarz MK, Rommel C. Nat Rev Drug Discov 5 903-918 (2006)
  14. Mammalian phosphoinositide kinases and phosphatases. Sasaki T, Takasuga S, Sasaki J, Kofuji S, Eguchi S, Yamazaki M, Suzuki A. Prog Lipid Res 48 307-343 (2009)
  15. Phosphoinositide 3-kinase signalling in the vascular system. Morello F, Perino A, Hirsch E. Cardiovasc Res 82 261-271 (2009)
  16. Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Mackay CR. Nat Immunol 9 988-998 (2008)
  17. PI3K inhibitors in inflammation, autoimmunity and cancer. Stark AK, Sriskantharajah S, Hessel EM, Hessel EM, Okkenhaug K. Curr Opin Pharmacol 23 82-91 (2015)
  18. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To ST, Li WP. Mol Cancer 16 100 (2017)
  19. More friend than foe: the emerging role of neutrophils in tissue repair. Peiseler M, Kubes P. J Clin Invest 129 2629-2639 (2019)
  20. Advances in neutrophil biology: clinical implications. Cowburn AS, Condliffe AM, Farahi N, Summers C, Chilvers ER. Chest 134 606-612 (2008)
  21. Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease. Gaki GS, Papavassiliou AG. Neuromolecular Med 16 217-230 (2014)
  22. Chemokine blockers--therapeutics in the making? Wells TN, Power CA, Shaw JP, Proudfoot AE. Trends Pharmacol Sci 27 41-47 (2006)
  23. Cancer-specific mutations in phosphatidylinositol 3-kinase. Vogt PK, Kang S, Elsliger MA, Gymnopoulos M. Trends Biochem Sci 32 342-349 (2007)
  24. Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. André S, Tough DF, Lacroix-Desmazes S, Kaveri SV, Bayry J. Am J Pathol 174 1575-1587 (2009)
  25. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. Ito K, Caramori G, Adcock IM. J Pharmacol Exp Ther 321 1-8 (2007)
  26. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Kong D, Yamori T. Cancer Sci 99 1734-1740 (2008)
  27. Modulation of the phosphoinositide 3-kinase signaling pathway alters host response to sepsis, inflammation, and ischemia/reperfusion injury. Williams DL, Ozment-Skelton T, Li C. Shock 25 432-439 (2006)
  28. Regulation of chemotaxis by the orchestrated activation of Ras, PI3K, and TOR. Sasaki AT, Firtel RA. Eur J Cell Biol 85 873-895 (2006)
  29. Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools. Ben Mkaddem S, Benhamou M, Monteiro RC. Front Immunol 10 811 (2019)
  30. The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis? Malemud CJ. Future Med Chem 7 1137-1147 (2015)
  31. New players in TLR-mediated innate immunity: PI3K and small Rho GTPases. Ruse M, Knaus UG. Immunol Res 34 33-48 (2006)
  32. Potential therapeutic targets for inflammation in toll-like receptor 4 (TLR4)-mediated signaling pathways. Roy A, Srivastava M, Saqib U, Liu D, Faisal SM, Sugathan S, Bishnoi S, Baig MS. Int Immunopharmacol 40 79-89 (2016)
  33. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Shuttleworth SJ, Silva FA, Cecil AR, Tomassi CD, Hill TJ, Raynaud FI, Clarke PA, Workman P. Curr Med Chem 18 2686-2714 (2011)
  34. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Foster JG, Blunt MD, Carter E, Ward SG. Pharmacol Rev 64 1027-1054 (2012)
  35. PI3K inhibition in inflammation: Toward tailored therapies for specific diseases. Ghigo A, Damilano F, Braccini L, Hirsch E. Bioessays 32 185-196 (2010)
  36. Elastin fragmentation and atherosclerosis progression: the elastokine concept. Maurice P, Blaise S, Gayral S, Debelle L, Laffargue M, Hornebeck W, Duca L. Trends Cardiovasc Med 23 211-221 (2013)
  37. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Uitdehaag JC, Verkaar F, Alwan H, de Man J, Buijsman RC, Zaman GJ. Br J Pharmacol 166 858-876 (2012)
  38. Future therapeutic targets in rheumatoid arthritis? Cheung TT, McInnes IB. Semin Immunopathol 39 487-500 (2017)
  39. Thiazolidine-2,4-diones: progress towards multifarious applications. Jain VS, Vora DK, Ramaa CS. Bioorg Med Chem 21 1599-1620 (2013)
  40. PI3Ks in lymphocyte signaling and development. Okkenhaug K, Fruman DA. Curr Top Microbiol Immunol 346 57-85 (2010)
  41. Inhibitory ITAMs: a matter of life and death. Pinheiro da Silva F, Aloulou M, Benhamou M, Monteiro RC. Trends Immunol 29 366-373 (2008)
  42. PI3K inhibitors in cardiovascular disease. Eisenreich A, Eisenreich A, Rauch U. Cardiovasc Ther 29 29-36 (2011)
  43. Recent advances in understanding neutrophils. Deniset JF, Kubes P. F1000Res 5 2912 (2016)
  44. Taming the PI3K team to hold inflammation and cancer at bay. Hirsch E, Ciraolo E, Ghigo A, Costa C. Pharmacol Ther 118 192-205 (2008)
  45. Twice upon a time: PI3K's secret double life exposed. Hirsch E, Braccini L, Ciraolo E, Morello F, Perino A. Trends Biochem Sci 34 244-248 (2009)
  46. Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. Medina-Tato DA, Ward SG, Watson ML. Immunology 121 448-461 (2007)
  47. T lymphocytes on the move: chemokines, PI 3-kinase and beyond. Ward SG. Trends Immunol 27 80-87 (2006)
  48. PI3K in cancer-stroma interactions: bad in seed and ugly in soil. Hirsch E, Ciraolo E, Franco I, Ghigo A, Martini M. Oncogene 33 3083-3090 (2014)
  49. Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma. Barzegar Behrooz A, Talaie Z, Jusheghani F, Łos MJ, Klonisch T, Ghavami S. Int J Mol Sci 23 1353 (2022)
  50. Neutrophil migration: moving from zebrafish models to human autoimmunity. Shelef MA, Tauzin S, Huttenlocher A. Immunol Rev 256 269-281 (2013)
  51. Structural Determinants of Isoform Selectivity in PI3K Inhibitors. Miller MS, Thompson PE, Gabelli SB. Biomolecules 9 E82 (2019)
  52. G protein betagamma subunits as targets for small molecule therapeutic development. Smrcka AV, Lehmann DM, Dessal AL. Comb Chem High Throughput Screen 11 382-395 (2008)
  53. Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders. Gross C, Bassell GJ. Front Mol Neurosci 7 12 (2014)
  54. Intracellular signal pathways: potential for therapies. Mavers M, Ruderman EM, Perlman H. Curr Rheumatol Rep 11 378-385 (2009)
  55. Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity. Taher TE, Bystrom J, Ong VH, Isenberg DA, Renaudineau Y, Abraham DJ, Mageed RA. Clin Rev Allergy Immunol 53 237-264 (2017)
  56. The chemical biology of phosphoinositide 3-kinases. Wymann MP, Schultz C. Chembiochem 13 2022-2035 (2012)
  57. Mechanisms of tissue damage in arthritis. Blüml S, Redlich K, Smolen JS. Semin Immunopathol 36 531-540 (2014)
  58. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia. Vangapandu HV, Jain N, Gandhi V. Expert Opin Investig Drugs 26 625-632 (2017)
  59. PI3Kγ in hypertension: a novel therapeutic target controlling vascular myogenic tone and target organ damage. Carnevale D, Lembo G. Cardiovasc Res 95 403-408 (2012)
  60. Phosphoinositide 3-kinase p110γ in immunity. Costa C, Martin-Conte EL, Hirsch E. IUBMB Life 63 707-713 (2011)
  61. Thiazolidine-2,4-dione derivatives: programmed chemical weapons for key protein targets of various pathological conditions. Chadha N, Bahia MS, Kaur M, Silakari O. Bioorg Med Chem 23 2953-2974 (2015)
  62. Primer: signal transduction in rheumatic disease--a clinician's guide. Sweeney SE, Firestein GS. Nat Clin Pract Rheumatol 3 651-660 (2007)
  63. Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety. Meier FM, McInnes IB. Best Pract Res Clin Rheumatol 28 605-624 (2014)
  64. Kinase inhibitors: a new tool for the treatment of rheumatoid arthritis. Chakravarty SD, Poulikakos PI, Ivashkiv LB, Salmon JE, Kalliolias GD. Clin Immunol 148 66-78 (2013)
  65. Novel inhibitors of the PI3K family. Carnero A. Expert Opin Investig Drugs 18 1265-1277 (2009)
  66. Garden of therapeutic delights: new targets in rheumatic diseases. Waldburger JM, Firestein GS. Arthritis Res Ther 11 206 (2009)
  67. Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseases-Implications for Therapeutic Approaches. Fetter T, Niebel D, Braegelmann C, Wenzel J. Cells 9 E2627 (2020)
  68. Inhibitors of phosphoinositide-3-kinase: a structure-based approach to understanding potency and selectivity. Sundstrom TJ, Anderson AC, Wright DL. Org Biomol Chem 7 840-850 (2009)
  69. Kinase inhibitors for cardiovascular disease. Kumar R, Singh VP, Baker KM. J Mol Cell Cardiol 42 1-11 (2007)
  70. Molecular control of PtdIns(3,4,5)P3 signaling in neutrophils. Luo HR, Mondal S. EMBO Rep 16 149-163 (2015)
  71. PIP3 pathway in regulatory T cells and autoimmunity. Kashiwada M, Lu P, Rothman PB. Immunol Res 39 194-224 (2007)
  72. Regulation of platelet plug formation by phosphoinositide metabolism. Min SH, Abrams CS. Blood 122 1358-1365 (2013)
  73. Lymphocyte signaling: regulation of FoxO transcription factors by microRNAs. Haftmann C, Stittrich AB, Sgouroudis E, Matz M, Chang HD, Radbruch A, Mashreghi MF. Ann N Y Acad Sci 1247 46-55 (2012)
  74. IL-17 in the rheumatologist's line of sight. Truchetet ME, Mossalayi MD, Boniface K. Biomed Res Int 2013 295132 (2013)
  75. Pathological survivin expression links viral infections with pathogenesis of erosive rheumatoid arthritis. Bokarewa M, Tarkowski A, Magnusson M. Scand J Immunol 66 192-198 (2007)
  76. Role of phosphoinositide 3-kinase signaling in autoimmunity. Oak JS, Fruman DA. Autoimmunity 40 433-441 (2007)
  77. Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design. Gabelli SB, Mandelker D, Schmidt-Kittler O, Vogelstein B, Amzel LM. Biochim Biophys Acta 1804 533-540 (2010)
  78. Negative regulation of human mononuclear phagocyte function. Hedl M, Abraham C. Mucosal Immunol 6 205-223 (2013)
  79. The role of PI3Kγ in the immune system: new insights and translational implications. Lanahan SM, Wymann MP, Lucas CL. Nat Rev Immunol 22 687-700 (2022)
  80. B-lymphocyte signalling abnormalities and lupus immunopathology. Taher TE, Muhammad HA, Bariller E, Flores-Borja F, Renaudineau Y, Isenberg DA, Mageed RA. Int Rev Immunol 32 428-444 (2013)
  81. Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase. Oak JS, Matheu MP, Parker I, Cahalan MD, Fruman DA. Biochem Soc Trans 35 1109-1113 (2007)
  82. Role of phosphoinositide 3-kinase in the pathogenesis of acute pancreatitis. Lupia E, Pigozzi L, Goffi A, Hirsch E, Montrucchio G. World J Gastroenterol 20 15190-15199 (2014)
  83. Development and application of PI3K assays for novel drug discovery. Yanamandra M, Mitra S, Giri A. Expert Opin Drug Discov 10 171-186 (2015)
  84. For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors. Buchanan CM, Lee KL, Shepherd PR. Biomolecules 9 E402 (2019)
  85. Leukocyte navigation mechanisms as targets in airway diseases. Medina-Tato DA, Watson ML, Ward SG. Drug Discov Today 11 866-879 (2006)
  86. PI3K inhibitors as potential therapeutics for autoimmune disease. Ball J, Archer S, Ward S. Drug Discov Today 19 1195-1199 (2014)
  87. ANCA-associated vasculitis: from bench research to novel treatments. Pallan L, Savage CO, Harper L. Nat Rev Nephrol 5 278-286 (2009)
  88. Emerging immunotherapies for rheumatoid arthritis. Reynolds G, Cooles FA, Isaacs JD, Hilkens CM. Hum Vaccin Immunother 10 822-837 (2014)
  89. Signalling via class IA PI3Ks. Stephens L, Hawkins P. Adv Enzyme Regul 51 27-36 (2011)
  90. Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets. Taher TE, Muhammad HA, Rahim A, Flores-Borja F, Renaudineau Y, Isenberg DA, Mageed RA. Eur J Clin Invest 43 866-880 (2013)
  91. Emerging therapies for colorectal cancer. Hezel AF, Ryan DP. Expert Opin Investig Drugs 16 867-876 (2007)
  92. T-cell-targeted signaling inhibitors. Won J, Lee GH. Int Rev Immunol 27 19-41 (2008)
  93. More paths to PI3Kγ. Stephens L, Hawkins P. PLoS Biol 11 e1001594 (2013)
  94. Decompartmentalizing target validation-thinking outside the pipeline boxes. Hooft van Huijsduijnen R, Rommel C. J Mol Med (Berl) 84 802-813 (2006)
  95. Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs. Poller W, Rother M, Skurk C, Scheibenbogen C. Br J Pharmacol 165 2044-2058 (2012)
  96. Phosphoinositide 3-Kinases as Potential Targets for Thrombosis Prevention. Setiabakti NM, Larsson P, Hamilton JR. Int J Mol Sci 23 4840 (2022)
  97. [Therapeutic potential of phosphoinositide 3-kinase inhibitors in rheumatoid arthritis]. Tamura N, Haruta K. Nihon Rinsho Meneki Gakkai Kaishi 30 369-374 (2007)

Articles citing this publication (368)

  1. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM. Cell 125 733-747 (2006)
  2. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, Knight ZA, Cobb BS, Cantrell D, O'Connor E, Shokat KM, Fisher AG, Merkenschlager M. Proc Natl Acad Sci U S A 105 7797-7802 (2008)
  3. PI3K signalling: the path to discovery and understanding. Vanhaesebroeck B, Stephens L, Hawkins P. Nat Rev Mol Cell Biol 13 195-203 (2012)
  4. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, Meek S, Smith AJ, Okkenhaug K, Vanhaesebroeck B. Proc Natl Acad Sci U S A 105 8292-8297 (2008)
  5. Differential regulation of protrusion and polarity by PI3K during neutrophil motility in live zebrafish. Yoo SK, Deng Q, Cavnar PJ, Wu YI, Hahn KM, Huttenlocher A. Dev Cell 18 226-236 (2010)
  6. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, Acevedo LM, Manglicmot JR, Song X, Wrasidlo W, Blair SL, Ginsberg MH, Cheresh DA, Hirsch E, Field SJ, Varner JA. Cancer Cell 19 715-727 (2011)
  7. Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nielsen SR, Quaranta V, Linford A, Emeagi P, Rainer C, Santos A, Ireland L, Sakai T, Sakai K, Kim YS, Engle D, Campbell F, Palmer D, Ko JH, Tuveson DA, Hirsch E, Mielgo A, Schmid MC. Nat Cell Biol 18 549-560 (2016)
  8. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Barber DF, Bartolomé A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C, Camps M, Rückle T, Schwarz MK, Rodríguez S, Martinez-A C, Balomenos D, Rommel C, Carrera AC. Nat Med 11 933-935 (2005)
  9. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, Finckh A, Smith DE, Gabay C. Arthritis Rheum 60 738-749 (2009)
  10. Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence. Sapey E, Greenwood H, Walton G, Mann E, Love A, Aaronson N, Insall RH, Stockley RA, Lord JM. Blood 123 239-248 (2014)
  11. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. Guiducci C, Ghirelli C, Marloie-Provost MA, Matray T, Coffman RL, Liu YJ, Barrat FJ, Soumelis V. J Exp Med 205 315-322 (2008)
  12. Small molecule disruption of G protein beta gamma subunit signaling inhibits neutrophil chemotaxis and inflammation. Lehmann DM, Seneviratne AM, Smrcka AV. Mol Pharmacol 73 410-418 (2008)
  13. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, Tomooka BH, Thomas FM, Song JJ, Goodman SB, Lee DM, Genovese MC, Utz PJ, Steinman L, Robinson WH. J Clin Invest 116 2633-2642 (2006)
  14. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, Macdougall JR, Ren P, Liu Y, Li LS, Jessen KA, Fritz CC, Dunbar JL, Porter JR, Rommel C, Palombella VJ, Changelian PS, Kutok JL. Chem Biol 20 1364-1374 (2013)
  15. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA. Cancer Res 67 7960-7965 (2007)
  16. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Lai Kwan Lam Q, King Hung Ko O, Zheng BJ, Lu L. Proc Natl Acad Sci U S A 105 14993-14998 (2008)
  17. The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Arcaro A, Guerreiro AS. Curr Genomics 8 271-306 (2007)
  18. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Aikawa Y, Morimoto K, Yamamoto T, Chaki H, Hashiramoto A, Narita H, Hirono S, Shiozawa S. Nat Biotechnol 26 817-823 (2008)
  19. Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) gamma2 and PI3Kgamma pathways. Mueller H, Stadtmann A, Van Aken H, Hirsch E, Wang D, Ley K, Zarbock A. Blood 115 3118-3127 (2010)
  20. The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Berndt A, Miller S, Williams O, Le DD, Houseman BT, Pacold JI, Gorrec F, Hon WC, Liu Y, Rommel C, Gaillard P, Rückle T, Schwarz MK, Shokat KM, Shaw JP, Williams RL. Nat Chem Biol 6 117-124 (2010)
  21. Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis. Son HJ, Lee J, Lee SY, Kim EK, Park MJ, Kim KW, Park SH, Cho ML. Mediators Inflamm 2014 973986 (2014)
  22. NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. Guo C, Fu R, Wang S, Huang Y, Li X, Zhou M, Zhao J, Yang N. Clin Exp Immunol 194 231-243 (2018)
  23. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Fröjdö S, Cozzone D, Vidal H, Pirola L. Biochem J 406 511-518 (2007)
  24. Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-akt hyperactivation in effector cells. Wehrens EJ, Mijnheer G, Duurland CL, Klein M, Meerding J, van Loosdregt J, de Jager W, Sawitzki B, Coffer PJ, Vastert B, Prakken BJ, van Wijk F. Blood 118 3538-3548 (2011)
  25. PI3Kγ is required for NMDA receptor-dependent long-term depression and behavioral flexibility. Kim JI, Lee HR, Sim SE, Baek J, Yu NK, Choi JH, Ko HG, Lee YS, Park SW, Kwak C, Ahn SJ, Choi SY, Kim H, Kim KH, Backx PH, Bradley CA, Kim E, Jang DJ, Lee K, Kim SJ, Zhuo M, Collingridge GL, Kaang BK. Nat Neurosci 14 1447-1454 (2011)
  26. Akt1 is critical for acute inflammation and histamine-mediated vascular leakage. Di Lorenzo A, Fernández-Hernando C, Cirino G, Sessa WC. Proc Natl Acad Sci U S A 106 14552-14557 (2009)
  27. Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Ong CJ, Ming-Lum A, Nodwell M, Ghanipour A, Yang L, Williams DE, Kim J, Demirjian L, Qasimi P, Ruschmann J, Cao LP, Ma K, Chung SW, Duronio V, Andersen RJ, Krystal G, Mui AL. Blood 110 1942-1949 (2007)
  28. ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Kong D, Yamori T. Cancer Sci 98 1638-1642 (2007)
  29. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Doukas J, Wrasidlo W, Noronha G, Dneprovskaia E, Fine R, Weis S, Hood J, Demaria A, Soll R, Cheresh D. Proc Natl Acad Sci U S A 103 19866-19871 (2006)
  30. Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation. Ji H, Rintelen F, Waltzinger C, Bertschy Meier D, Bilancio A, Pearce W, Hirsch E, Wymann MP, Rückle T, Camps M, Vanhaesebroeck B, Okkenhaug K, Rommel C. Blood 110 2940-2947 (2007)
  31. Oncogenic signaling of class I PI3K isoforms. Denley A, Kang S, Karst U, Vogt PK. Oncogene 27 2561-2574 (2008)
  32. Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils. Randis TM, Puri KD, Zhou H, Diacovo TG. Eur J Immunol 38 1215-1224 (2008)
  33. Role of phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets. Kim S, Mangin P, Dangelmaier C, Lillian R, Jackson SP, Daniel JL, Kunapuli SP. J Biol Chem 284 33763-33772 (2009)
  34. p110gamma and p110delta phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells. Tassi I, Cella M, Gilfillan S, Turnbull I, Diacovo TG, Penninger JM, Colonna M. Immunity 27 214-227 (2007)
  35. IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production. Maeda K, Mehta H, Drevets DA, Coggeshall KM. Blood 115 4699-4706 (2010)
  36. Oxidative stress dependent microRNA-34a activation via PI3Kα reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells. Baker JR, Vuppusetty C, Colley T, Papaioannou AI, Fenwick P, Donnelly L, Ito K, Barnes PJ. Sci Rep 6 35871 (2016)
  37. Resveratrol inhibits TNF-α-induced IL-1β, MMP-3 production in human rheumatoid arthritis fibroblast-like synoviocytes via modulation of PI3kinase/Akt pathway. Tian J, Chen JW, Gao JS, Li L, Xie X. Rheumatol Int 33 1829-1835 (2013)
  38. Transforming growth factor β-transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg/Th17 cells and osteoclastogenesis. Park MJ, Park HS, Cho ML, Oh HJ, Cho YG, Min SY, Chung BH, Lee JW, Kim HY, Cho SG. Arthritis Rheum 63 1668-1680 (2011)
  39. Interleukin-10 produced by myeloid-derived suppressor cells is critical for the induction of Tregs and attenuation of rheumatoid inflammation in mice. Park MJ, Lee SH, Kim EK, Lee EJ, Baek JA, Park SH, Kwok SK, Cho ML. Sci Rep 8 3753 (2018)
  40. Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. Ali K, Camps M, Pearce WP, Ji H, Rückle T, Kuehn N, Pasquali C, Chabert C, Rommel C, Vanhaesebroeck B. J Immunol 180 2538-2544 (2008)
  41. Rab8a interacts directly with PI3Kγ to modulate TLR4-driven PI3K and mTOR signalling. Luo L, Wall AA, Yeo JC, Condon ND, Norwood SJ, Schoenwaelder S, Chen KW, Jackson S, Jenkins BJ, Hartland EL, Schroder K, Collins BM, Sweet MJ, Stow JL. Nat Commun 5 4407 (2014)
  42. Promotion of cancer cell invasiveness and metastasis emergence caused by olfactory receptor stimulation. Sanz G, Leray I, Dewaele A, Sobilo J, Lerondel S, Bouet S, Grébert D, Monnerie R, Pajot-Augy E, Mir LM. PLoS One 9 e85110 (2014)
  43. A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation. Bergamini G, Bell K, Shimamura S, Werner T, Cansfield A, Müller K, Perrin J, Rau C, Ellard K, Hopf C, Doce C, Leggate D, Mangano R, Mathieson T, O'Mahony A, Plavec I, Rharbaoui F, Reinhard F, Savitski MM, Ramsden N, Hirsch E, Drewes G, Rausch O, Bantscheff M, Neubauer G. Nat Chem Biol 8 576-582 (2012)
  44. Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis. Chang JD, Sukhova GK, Libby P, Schvartz E, Lichtenstein AH, Field SJ, Kennedy C, Madhavarapu S, Luo J, Wu D, Cantley LC. Proc Natl Acad Sci U S A 104 8077-8082 (2007)
  45. Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of I kappa B alpha in anti-inflammatory effect of gemfibrozil in microglia. Jana M, Jana A, Liu X, Ghosh S, Pahan K. J Immunol 179 4142-4152 (2007)
  46. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov AV, Gurova KV. Oncogene 28 1151-1161 (2009)
  47. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Amin MA, Mansfield PJ, Pakozdi A, Campbell PL, Ahmed S, Martinez RJ, Koch AE. Arthritis Rheum 56 1787-1797 (2007)
  48. Neutrophil recruitment limited by high-affinity bent β2 integrin binding ligand in cis. Fan Z, McArdle S, Marki A, Mikulski Z, Gutierrez E, Engelhardt B, Deutsch U, Ginsberg M, Groisman A, Ley K. Nat Commun 7 12658 (2016)
  49. Leukocyte phosphoinositide-3 kinase {gamma} is required for chemokine-induced, sustained adhesion under flow in vivo. Smith DF, Deem TL, Bruce AC, Reutershan J, Wu D, Ley K. J Leukoc Biol 80 1491-1499 (2006)
  50. The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Kim N, Saudemont A, Webb L, Camps M, Ruckle T, Hirsch E, Turner M, Colucci F. Blood 110 3202-3208 (2007)
  51. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. Doukas J, Eide L, Stebbins K, Racanelli-Layton A, Dellamary L, Martin M, Dneprovskaia E, Noronha G, Soll R, Wrasidlo W, Acevedo LM, Cheresh DA. J Pharmacol Exp Ther 328 758-765 (2009)
  52. Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2. de Oliveira AC, Candelario-Jalil E, Bhatia HS, Lieb K, Hüll M, Fiebich BL. Glia 56 844-855 (2008)
  53. Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation. Zhang H, Wang S, Huang Y, Wang H, Zhao J, Gaskin F, Yang N, Fu SM. Clin Immunol 157 175-186 (2015)
  54. PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomy. Jackson LN, Larson SD, Silva SR, Rychahou PG, Chen LA, Qiu S, Rajaraman S, Evers BM. Am J Physiol Gastrointest Liver Physiol 294 G1401-10 (2008)
  55. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. Garcia A, Kim S, Bhavaraju K, Schoenwaelder SM, Kunapuli SP. Biochem J 429 369-377 (2010)
  56. PI3K/Akt signaling pathway is involved in the pathogenesis of ulcerative colitis. Huang XL, Xu J, Zhang XH, Qiu BY, Peng L, Zhang M, Gan HT. Inflamm Res 60 727-734 (2011)
  57. Pituitary adenylate cyclase-activating polypeptide (PACAP)/PAC1HOP1 receptor activation coordinates multiple neurotrophic signaling pathways: Akt activation through phosphatidylinositol 3-kinase gamma and vesicle endocytosis for neuronal survival. May V, Lutz E, MacKenzie C, Schutz KC, Dozark K, Braas KM. J Biol Chem 285 9749-9761 (2010)
  58. A role for a CXCR2/phosphatidylinositol 3-kinase gamma signaling axis in acute and chronic vascular permeability. Gavard J, Gavard J, Hou X, Qu Y, Masedunskas A, Martin D, Weigert R, Li X, Gutkind JS. Mol Cell Biol 29 2469-2480 (2009)
  59. Chemokine CXCL12 uses CXCR4 and a signaling core formed by bifunctional Akt, extracellular signal-regulated kinase (ERK)1/2, and mammalian target of rapamycin complex 1 (mTORC1) proteins to control chemotaxis and survival simultaneously in mature dendritic cells. Delgado-Martín C, Escribano C, Pablos JL, Riol-Blanco L, Rodríguez-Fernández JL. J Biol Chem 286 37222-37236 (2011)
  60. Signaling mechanism of HIV-1 gp120 and virion-induced IL-1beta release in primary human macrophages. Cheung R, Ravyn V, Wang L, Ptasznik A, Collman RG. J Immunol 180 6675-6684 (2008)
  61. Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues. Shahrara S, Castro-Rueda HP, Haines GK, Koch AE. Arthritis Res Ther 9 R112 (2007)
  62. Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice. Siragusa M, Katare R, Meloni M, Damilano F, Hirsch E, Emanueli C, Madeddu P. Circ Res 106 757-768 (2010)
  63. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Puri KD, Gold MR. Front Immunol 3 256 (2012)
  64. The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases. Banham-Hall E, Clatworthy MR, Okkenhaug K. Open Rheumatol J 6 245-258 (2012)
  65. Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. Bocelli-Tyndall C, Zajac P, Di Maggio N, Trella E, Benvenuto F, Iezzi G, Scherberich A, Barbero A, Schaeren S, Pistoia V, Spagnoli G, Vukcevic M, Martin I, Tyndall A. Arthritis Rheum 62 3815-3825 (2010)
  66. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. Kong D, Dan S, Yamazaki K, Yamori T. Eur J Cancer 46 1111-1121 (2010)
  67. Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Ban K, Cooper AJ, Samuel S, Bhatti A, Patel M, Izumo S, Penninger JM, Backx PH, Oudit GY, Tsushima RG. Circ Res 103 643-653 (2008)
  68. Ras is an indispensable coregulator of the class IB phosphoinositide 3-kinase p87/p110gamma. Kurig B, Shymanets A, Bohnacker T, Prajwal, Brock C, Ahmadian MR, Schaefer M, Gohla A, Harteneck C, Wymann MP, Jeanclos E, Nürnberg B. Proc Natl Acad Sci U S A 106 20312-20317 (2009)
  69. Interferon-gamma regulates inflammatory cell death by targeting necroptosis in experimental autoimmune arthritis. Lee SH, Kwon JY, Kim SY, Jung K, Cho ML. Sci Rep 7 10133 (2017)
  70. Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase. Martin AL, Schwartz MD, Jameson SC, Shimizu Y. J Immunol 180 2081-2088 (2008)
  71. Mechanisms involved in IL-6-induced muscular mechanical hyperalgesia in mice. Manjavachi MN, Motta EM, Marotta DM, Leite DFP, Calixto JB. Pain 151 345-355 (2010)
  72. NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth. Jaba IM, Zhuang ZW, Li N, Jiang Y, Martin KA, Sinusas AJ, Papademetris X, Simons M, Sessa WC, Young LH, Tirziu D. J Clin Invest 123 1718-1731 (2013)
  73. Blockade of phosphatidylinositol 3-kinase PI3Kδ or PI3Kγ reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis. Roller A, Perino A, Dapavo P, Soro E, Okkenhaug K, Hirsch E, Ji H. J Immunol 189 4612-4620 (2012)
  74. Parallel phosphatidylinositol 3-kinase (PI3K)-dependent and Src-dependent pathways lead to CXCL8-mediated Rac2 activation and chemotaxis. Sai J, Raman D, Liu Y, Wikswo J, Richmond A. J Biol Chem 283 26538-26547 (2008)
  75. Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase γ activity in pressure overload-induced cardiac failure. Damilano F, Franco I, Perrino C, Schaefer K, Azzolino O, Carnevale D, Cifelli G, Carullo P, Ragona R, Ghigo A, Perino A, Lembo G, Hirsch E. Circulation 123 391-399 (2011)
  76. Phosphoinositol 3-kinase-gamma mediates antineutrophil cytoplasmic autoantibody-induced glomerulonephritis. Schreiber A, Rolle S, Peripelittchenko L, Rademann J, Schneider W, Luft FC, Kettritz R. Kidney Int 77 118-128 (2010)
  77. p53 controls autoimmune arthritis via STAT-mediated regulation of the Th17 cell/Treg cell balance in mice. Park JS, Lim MA, Cho ML, Ryu JG, Moon YM, Jhun JY, Byun JK, Kim EK, Hwang SY, Ju JH, Kwok SK, Kim HY. Arthritis Rheum 65 949-959 (2013)
  78. RACK1 regulates directional cell migration by acting on G betagamma at the interface with its effectors PLC beta and PI3K gamma. Chen S, Lin F, Shin ME, Wang F, Shen L, Hamm HE. Mol Biol Cell 19 3909-3922 (2008)
  79. An arrestin-dependent multi-kinase signaling complex mediates MIP-1beta/CCL4 signaling and chemotaxis of primary human macrophages. Cheung R, Malik M, Ravyn V, Tomkowicz B, Ptasznik A, Collman RG. J Leukoc Biol 86 833-845 (2009)
  80. Drug-loaded gold/iron/gold plasmonic nanoparticles for magnetic targeted chemo-photothermal treatment of rheumatoid arthritis. Kim HJ, Lee SM, Park KH, Mun CH, Park YB, Yoo KH. Biomaterials 61 95-102 (2015)
  81. PI3Kgamma is a key regulator of inflammatory responses and cardiovascular homeostasis. Hawkins PT, Stephens LR. Science 318 64-66 (2007)
  82. Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs. Williams O, Houseman BT, Kunkel EJ, Aizenstein B, Hoffman R, Knight ZA, Shokat KM. Chem Biol 17 123-134 (2010)
  83. Insulin granule recruitment and exocytosis is dependent on p110gamma in insulinoma and human beta-cells. Pigeau GM, Kolic J, Ball BJ, Hoppa MB, Wang YW, Rückle T, Woo M, Manning Fox JE, MacDonald PE. Diabetes 58 2084-2092 (2009)
  84. PI3K gamma-deficient mice have reduced levels of allergen-induced eosinophilic inflammation and airway remodeling. Lim DH, Cho JY, Song DJ, Lee SY, Miller M, Broide DH. Am J Physiol Lung Cell Mol Physiol 296 L210-9 (2009)
  85. The phosphatidylinositol 3-kinase signaling pathway exerts protective effects during sepsis by controlling C5a-mediated activation of innate immune functions. Wrann CD, Tabriz NA, Barkhausen T, Klos A, van Griensven M, Pape HC, Kendoff DO, Guo R, Ward PA, Krettek C, Riedemann NC. J Immunol 178 5940-5948 (2007)
  86. Enhanced immunoregulation of mesenchymal stem cells by IL-10-producing type 1 regulatory T cells in collagen-induced arthritis. Lim JY, Im KI, Lee ES, Kim N, Nam YS, Jeon YW, Cho SG. Sci Rep 6 26851 (2016)
  87. Grape seed proanthocyanidin extract (GSPE) attenuates collagen-induced arthritis. Cho ML, Heo YJ, Park MK, Oh HJ, Park JS, Woo YJ, Ju JH, Park SH, Kim HY, Min JK. Immunol Lett 124 102-110 (2009)
  88. The phosphoinositide-3 kinase gamma-Akt pathway mediates renal tubular injury in cisplatin nephrotoxicity. Kuwana H, Terada Y, Kobayashi T, Okado T, Penninger JM, Irie-Sasaki J, Sasaki T, Sasaki S. Kidney Int 73 430-445 (2008)
  89. Tissue- and stimulus-dependent role of phosphatidylinositol 3-kinase isoforms for neutrophil recruitment induced by chemoattractants in vivo. Pinho V, Russo RC, Amaral FA, de Sousa LP, Barsante MM, de Souza DG, Alves-Filho JC, Cara DC, Hayflick JS, Rommel C, Ruckle T, Rossi AG, Teixeira MM. J Immunol 179 7891-7898 (2007)
  90. Endothelial p110γPI3K Mediates Endothelial Regeneration and Vascular Repair After Inflammatory Vascular Injury. Huang X, Dai Z, Cai L, Sun K, Cho J, Albertine KH, Malik AB, Schraufnagel DE, Zhao YY. Circulation 133 1093-1103 (2016)
  91. Phosphatidylinositol-3-kinase-gamma is integral to homing functions of progenitor cells. Chavakis E, Carmona G, Urbich C, Göttig S, Henschler R, Penninger JM, Zeiher AM, Chavakis T, Dimmeler S. Circ Res 102 942-949 (2008)
  92. Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). Rewcastle GW, Gamage SA, Flanagan JU, Frederick R, Denny WA, Baguley BC, Kestell P, Singh R, Kendall JD, Marshall ES, Lill CL, Lee WJ, Kolekar S, Buchanan CM, Jamieson SM, Shepherd PR. J Med Chem 54 7105-7126 (2011)
  93. Genistein suppresses tumor necrosis factor α-induced inflammation via modulating reactive oxygen species/Akt/nuclear factor κB and adenosine monophosphate-activated protein kinase signal pathways in human synoviocyte MH7A cells. Li J, Li J, Yue Y, Hu Y, Cheng W, Liu R, Pan X, Zhang P. Drug Des Devel Ther 8 315-323 (2014)
  94. PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis. Hayer S, Pundt N, Peters MA, Wunrau C, Kühnel I, Neugebauer K, Strietholt S, Zwerina J, Korb A, Penninger J, Joosten LA, Gay S, Rückle T, Schett G, Pap T. FASEB J 23 4288-4298 (2009)
  95. Differential roles for the p101 and p84 regulatory subunits of PI3Kγ in tumor growth and metastasis. Brazzatti JA, Klingler-Hoffmann M, Haylock-Jacobs S, Harata-Lee Y, Niu M, Higgins MD, Kochetkova M, Hoffmann P, McColl SR. Oncogene 31 2350-2361 (2012)
  96. PINK1 Deficiency Enhances Inflammatory Cytokine Release from Acutely Prepared Brain Slices. Kim J, Byun JW, Choi I, Kim B, Jeong HK, Jou I, Joe E. Exp Neurobiol 22 38-44 (2013)
  97. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE, Fruman DA. Blood 109 2894-2902 (2007)
  98. The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Ohno H, Uemura Y, Murooka H, Takanashi H, Tokieda T, Ohzeki Y, Kubo K, Serizawa I. Eur J Immunol 38 283-291 (2008)
  99. Insulin-like growth factor-1 regulates platelet activation through PI3-Kalpha isoform. Kim S, Garcia A, Jackson SP, Kunapuli SP. Blood 110 4206-4213 (2007)
  100. Matricellular signaling molecule CCN1 attenuates experimental autoimmune myocarditis by acting as a novel immune cell migration modulator. Rother M, Krohn S, Kania G, Vanhoutte D, Eisenreich A, Wang X, Westermann D, Savvatis K, Dannemann N, Skurk C, Hilfiker-Kleiner D, Cathomen T, Fechner H, Rauch U, Schultheiss HP, Heymans S, Eriksson U, Scheibenbogen C, Poller W. Circulation 122 2688-2698 (2010)
  101. Phosphoinositide 3-kinase gamma inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment. Ferrandi C, Ardissone V, Ferro P, Rückle T, Zaratin P, Ammannati E, Hauben E, Rommel C, Cirillo R. J Pharmacol Exp Ther 322 923-930 (2007)
  102. Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. Kong D, Yaguchi S, Yamori T. Biol Pharm Bull 32 297-300 (2009)
  103. Interleukin-2/anti-interleukin-2 monoclonal antibody immune complex suppresses collagen-induced arthritis in mice by fortifying interleukin-2/STAT5 signalling pathways. Lee SY, Cho ML, Oh HJ, Ryu JG, Park MJ, Jhun JY, Park MK, Stone JC, Ju JH, Hwang SY, Park SH, Surh CD, Kim HY. Immunology 137 305-316 (2012)
  104. The p110gamma isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites. Thomas MS, Mitchell JS, DeNucci CC, Martin AL, Shimizu Y. J Leukoc Biol 84 814-823 (2008)
  105. A membrane capture assay for lipid kinase activity. Knight ZA, Feldman ME, Balla A, Balla T, Shokat KM. Nat Protoc 2 2459-2466 (2007)
  106. Current Screens Based on the AlphaScreen Technology for Deciphering Cell Signalling Pathways. Taouji S, Dahan S, Bossé R, Chevet E. Curr Genomics 10 93-101 (2009)
  107. Effect of particle size on the biodistribution of nano- and microparticles following intra-articular injection in mice. Pradal J, Maudens P, Gabay C, Seemayer CA, Jordan O, Allémann E. Int J Pharm 498 119-129 (2016)
  108. Inhibition of the PI3K-Akt signaling pathway reduces tumor necrosis factor-alpha production in response to titanium particles in vitro. Smith MV, Lee MJ, Islam AS, Rohrer JL, Goldberg VM, Beidelschies MA, Greenfield EM. J Bone Joint Surg Am 89 1019-1027 (2007)
  109. Activation of spinal phosphatidylinositol 3-kinase/protein kinase B mediates pain behavior induced by plantar incision in mice. Xu B, Guan XH, Yu JX, Lv J, Zhang HX, Fu QC, Xiang HB, Bu HL, Shi D, Shu B, Qin LS, Manyande A, Tian YK. Exp Neurol 255 71-82 (2014)
  110. Blockade of class IB phosphoinositide-3 kinase ameliorates obesity-induced inflammation and insulin resistance. Kobayashi N, Ueki K, Okazaki Y, Iwane A, Kubota N, Ohsugi M, Awazawa M, Kobayashi M, Sasako T, Kaneko K, Suzuki M, Nishikawa Y, Hara K, Yoshimura K, Koshima I, Goyama S, Murakami K, Sasaki J, Nagai R, Kurokawa M, Sasaki T, Kadowaki T. Proc Natl Acad Sci U S A 108 5753-5758 (2011)
  111. Cigarette smoke and α,β-unsaturated aldehydes elicit VEGF release through the p38 MAPK pathway in human airway smooth muscle cells and lung fibroblasts. Volpi G, Facchinetti F, Moretto N, Civelli M, Patacchini R. Br J Pharmacol 163 649-661 (2011)
  112. Crystal Structures of PI3Kα Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design. Zhao Y, Zhang X, Chen Y, Lu S, Peng Y, Wang X, Guo C, Zhou A, Zhang J, Luo Y, Shen Q, Ding J, Meng L, Zhang J. ACS Med Chem Lett 5 138-142 (2014)
  113. Involvement of phosphoinositide 3-kinase gamma in the neuro-inflammatory response and cognitive impairments induced by beta-amyloid 1-40 peptide in mice. Passos GF, Figueiredo CP, Prediger RD, Silva KA, Siqueira JM, Duarte FS, Leal PC, Medeiros R, Calixto JB. Brain Behav Immun 24 493-501 (2010)
  114. Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERK MAP kinase phosphorylation. Santos LL, Dacumos A, Yamana J, Sharma L, Morand EF. Clin Exp Immunol 152 372-380 (2008)
  115. PI3Kγ inhibition reduces blood pressure by a vasorelaxant Akt/L-type calcium channel mechanism. Carnevale D, Vecchione C, Mascio G, Esposito G, Cifelli G, Martinello K, Landolfi A, Selvetella G, Grieco P, Damato A, Franco E, Haase H, Maffei A, Ciraolo E, Fucile S, Frati G, Mazzoni O, Hirsch E, Lembo G. Cardiovasc Res 93 200-209 (2012)
  116. Survivin is an essential mediator of arthritis interacting with urokinase signalling. Baran M, Möllers LN, Andersson S, Jonsson IM, Ekwall AK, Bjersing J, Tarkowski A, Bokarewa M. J Cell Mol Med 13 3797-3808 (2009)
  117. GBF1 bears a novel phosphatidylinositol-phosphate binding module, BP3K, to link PI3Kγ activity with Arf1 activation involved in GPCR-mediated neutrophil chemotaxis and superoxide production. Mazaki Y, Nishimura Y, Sabe H. Mol Biol Cell 23 2457-2467 (2012)
  118. Short-term hypoxia enhances the migratory capability of dendritic cell through HIF-1α and PI3K/Akt pathway. Filippi I, Morena E, Aldinucci C, Carraro F, Sozzani S, Naldini A. J Cell Physiol 229 2067-2076 (2014)
  119. PI3Kγ kinase activity is required for optimal T-cell activation and differentiation. Ladygina N, Gottipati S, Ngo K, Castro G, Ma JY, Banie H, Rao TS, Fung-Leung WP. Eur J Immunol 43 3183-3196 (2013)
  120. Phosphatidylinositol-3-kinase p110γ contributes to bile salt-induced apoptosis in primary rat hepatocytes and human hepatoma cells. Hohenester S, Gates A, Wimmer R, Beuers U, Anwer MS, Rust C, Webster CR. J Hepatol 53 918-926 (2010)
  121. Phosphoinositide 3-Kinase Gamma Contributes to Neuroinflammation in a Rat Model of Surgical Brain Injury. Huang L, Sherchan P, Wang Y, Reis C, Applegate RL, Tang J, Zhang JH. J Neurosci 35 10390-10401 (2015)
  122. SHIP prevents lipopolysaccharide from triggering an antiviral response in mice. Sly LM, Hamilton MJ, Kuroda E, Ho VW, Antignano FL, Omeis SL, van Netten-Thomas CJ, Wong D, Brugger HK, Williams O, Feldman ME, Houseman BT, Fiedler D, Shokat KM, Krystal G. Blood 113 2945-2954 (2009)
  123. A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis. Yuzugullu H, Baitsch L, Von T, Steiner A, Tong H, Ni J, Clayton LK, Bronson R, Roberts TM, Gritsman K, Zhao JJ. Nat Commun 6 8501 (2015)
  124. Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants. Hartkamp LM, Fine JS, van Es IE, Tang MW, Smith M, Woods J, Narula S, DeMartino J, Tak PP, Reedquist KA. Ann Rheum Dis 74 1603-1611 (2015)
  125. E2F2 directly regulates the STAT1 and PI3K/AKT/NF-κB pathways to exacerbate the inflammatory phenotype in rheumatoid arthritis synovial fibroblasts and mouse embryonic fibroblasts. Wang S, Wang L, Wu C, Sun S, Pan JH. Arthritis Res Ther 20 225 (2018)
  126. Gene expression signatures of target tissues in type 1 diabetes, lupus erythematosus, multiple sclerosis, and rheumatoid arthritis. Szymczak F, Colli ML, Mamula MJ, Evans-Molina C, Eizirik DL. Sci Adv 7 eabd7600 (2021)
  127. Inhibitor of PI3Kγ ameliorates TNBS-induced colitis in mice by affecting the functional activity of CD4+CD25+FoxP3+ regulatory T cells. Dutra RC, Cola M, Leite DF, Bento AF, Claudino RF, Nascimento AF, Leal PC, Calixto JB. Br J Pharmacol 163 358-374 (2011)
  128. Inhibitory odorant signaling in Mammalian olfactory receptor neurons. Ukhanov K, Corey EA, Brunert D, Klasen K, Ache BW. J Neurophysiol 103 1114-1122 (2010)
  129. Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer. González-García A, Sánchez-Ruiz J, Flores JM, Carrera AC. Gastroenterology 138 1374-1383 (2010)
  130. Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. Xie P, Williams DS, Atilla-Gokcumen GE, Milk L, Xiao M, Smalley KS, Herlyn M, Meggers E, Marmorstein R. ACS Chem Biol 3 305-316 (2008)
  131. Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis. Cummings HE, Barbi J, Reville P, Oghumu S, Zorko N, Sarkar A, Keiser TL, Lu B, Rückle T, Varikuti S, Lezama-Davila C, Wewers MD, Whitacre C, Radzioch D, Rommel C, Seveau S, Satoskar AR. Proc Natl Acad Sci U S A 109 1251-1256 (2012)
  132. Foxo4- and Stat3-dependent IL-10 production by progranulin in regulatory T cells restrains inflammatory arthritis. Fu W, Hu W, Shi L, Mundra JJ, Xiao G, Dustin ML, Liu CJ. FASEB J 31 1354-1367 (2017)
  133. Murine bone marrow-derived macrophages differentiated with GM-CSF become foam cells by PI3Kγ-dependent fluid-phase pinocytosis of native LDL. Anzinger JJ, Chang J, Xu Q, Barthwal MK, Bohnacker T, Wymann MP, Kruth HS. J Lipid Res 53 34-42 (2012)
  134. PI3K class II α regulates δ-opioid receptor export from the trans-Golgi network. Shiwarski DJ, Darr M, Telmer CA, Bruchez MP, Puthenveedu MA. Mol Biol Cell 28 2202-2219 (2017)
  135. Synoviocyte stimulation by the LFA-1-intercellular adhesion molecule-2-Ezrin-Akt pathway in rheumatoid arthritis. Singh K, Colmegna I, He X, Weyand CM, Goronzy JJ. J Immunol 180 1971-1978 (2008)
  136. The regulatory subunits of PI3Kγ control distinct neutrophil responses. Deladeriere A, Gambardella L, Pan D, Anderson KE, Hawkins PT, Stephens LR. Sci Signal 8 ra8 (2015)
  137. Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I. Am J Hematol 93 1318-1326 (2018)
  138. Epigallocatechin-3-gallate ameliorates both obesity and autoinflammatory arthritis aggravated by obesity by altering the balance among CD4+ T-cell subsets. Byun JK, Yoon BY, Jhun JY, Oh HJ, Kim EK, Min JK, Cho ML. Immunol Lett 157 51-59 (2014)
  139. Myeloid-specific deletion of tumor suppressor PTEN augments neutrophil transendothelial migration during inflammation. Sarraj B, Massberg S, Li Y, Kasorn A, Subramanian K, Loison F, Silberstein LE, von Andrian U, Luo HR. J Immunol 182 7190-7200 (2009)
  140. Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis. Asnagli H, Martire D, Belmonte N, Quentin J, Bastian H, Boucard-Jourdin M, Fall PB, Mausset-Bonnefont AL, Mantello-Moreau A, Rouquier S, Marchetti I, Jorgensen C, Foussat A, Louis-Plence P. Arthritis Res Ther 16 R115 (2014)
  141. A multitude of kinases--which are the best targets in treating rheumatoid arthritis? Lindstrom TM, Robinson WH. Rheum Dis Clin North Am 36 367-383 (2010)
  142. Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists. Webb A, Johnson A, Fortunato M, Platt A, Crabbe T, Christie MI, Watt GF, Ward SG, Jopling LA. J Leukoc Biol 84 1202-1212 (2008)
  143. Important roles of PI3Kgamma in osteoclastogenesis and bone homeostasis. Kang H, Chang W, Hurley M, Vignery A, Wu D. Proc Natl Acad Sci U S A 107 12901-12906 (2010)
  144. Intravenous immunoglobulin attenuates experimental autoimmune arthritis by inducing reciprocal regulation of Th17 and Treg cells in an interleukin-10-dependent manner. Lee SY, Jung YO, Ryu JG, Kang CM, Kim EK, Son HJ, Yang EJ, Ju JH, Kang YS, Park SH, Kim HY, Cho ML. Arthritis Rheumatol 66 1768-1778 (2014)
  145. Mechanisms of transient signaling via short and long prolactin receptor isoforms in female and male sensory neurons. Belugin S, Diogenes AR, Patil MJ, Ginsburg E, Henry MA, Akopian AN. J Biol Chem 288 34943-34955 (2013)
  146. Mesenchymal stem cells alleviate experimental rheumatoid arthritis through microRNA-regulated IκB expression. Yan X, Cen Y, Wang Q. Sci Rep 6 28915 (2016)
  147. PI3Kgamma is the dominant isoform involved in migratory responses of human T lymphocytes: effects of ex vivo maintenance and limitations of non-viral delivery of siRNA. Smith LD, Hickman ES, Parry RV, Westwick J, Ward SG. Cell Signal 19 2528-2539 (2007)
  148. Phosphatidylinositol 3-kinase-γ signaling promotes Campylobacter jejuni-induced colitis through neutrophil recruitment in mice. Sun X, Liu B, Sartor RB, Jobin C. J Immunol 190 357-365 (2013)
  149. Treatment of Collagen-Induced Arthritis Using Immune Modulatory Properties of Human Mesenchymal Stem Cells. Park KH, Mun CH, Kang MI, Lee SW, Lee SK, Park YB. Cell Transplant 25 1057-1072 (2016)
  150. A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2. Petrilli AM, Fuse MA, Donnan MS, Bott M, Sparrow NA, Tondera D, Huffziger J, Frenzel C, Malany CS, Echeverri CJ, Smith L, Fernández-Valle C. Am J Transl Res 6 471-493 (2014)
  151. Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway. Bruce I, Akhlaq M, Bloomfield GC, Budd E, Cox B, Cuenoud B, Finan P, Gedeck P, Hatto J, Hayler JF, Head D, Keller T, Kirman L, Leblanc C, Le Grand D, McCarthy C, O'Connor D, Owen C, Oza MS, Pilgrim G, Press NE, Sviridenko L, Whitehead L. Bioorg Med Chem Lett 22 5445-5450 (2012)
  152. Digoxin ameliorates autoimmune arthritis via suppression of Th17 differentiation. Lee J, Baek S, Lee J, Lee J, Lee DG, Park MK, Cho ML, Park SH, Kwok SK. Int Immunopharmacol 26 103-111 (2015)
  153. Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency. Martin P, Talabot-Ayer D, Seemayer CA, Vigne S, Lamacchia C, Rodriguez E, Finckh A, Smith DE, Gabay C, Palmer G. Arthritis Res Ther 15 R13 (2013)
  154. GTS-21 attenuates lipopolysaccharide-induced inflammatory cytokine production in vitro by modulating the Akt and NF-κB signaling pathway through the α7 nicotinic acetylcholine receptor. Yue Y, Liu R, Cheng W, Hu Y, Li J, Pan X, Peng J, Zhang P. Int Immunopharmacol 29 504-512 (2015)
  155. High ambient glucose induces angiotensin-independent AT-1 receptor activation, leading to increases in proliferation and extracellular matrix accumulation in MES-13 mesangial cells. Yano N, Suzuki D, Endoh M, Cao TN, Dahdah JR, Tseng A, Stabila JP, McGonnigal BG, Padbury JF, Tseng YT. Biochem J 423 129-143 (2009)
  156. IL-17-deficient allogeneic bone marrow transplantation prevents the induction of collagen-induced arthritis in DBA/1J mice. Park MJ, Park HS, Oh HJ, Lim JY, Yoon BY, Kim HY, Cho ML, Cho SG. Exp Mol Med 44 694-705 (2012)
  157. A chemical proteomics approach to phosphatidylinositol 3-kinase signaling in macrophages. Pasquali C, Bertschy-Meier D, Chabert C, Curchod ML, Arod C, Booth R, Mechtler K, Vilbois F, Xenarios I, Ferguson CG, Prestwich GD, Camps M, Rommel C. Mol Cell Proteomics 6 1829-1841 (2007)
  158. Inhibiting inflammation in rheumatoid arthritis. Firestein GS. N Engl J Med 354 80-82 (2006)
  159. Isoform-selective inhibition of phosphoinositide 3-kinase: identification of a new region of nonconserved amino acids critical for p110α inhibition. Zheng Z, Amran SI, Thompson PE, Jennings IG. Mol Pharmacol 80 657-664 (2011)
  160. PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia. Silveira AB, Laranjeira AB, Rodrigues GO, Leal PC, Cardoso BA, Barata JT, Yunes RA, Zanchin NI, Brandalise SR, Yunes JA. Oncotarget 6 13105-13118 (2015)
  161. Role of protein arginine methyltransferase 5 in inflammation and migration of fibroblast-like synoviocytes in rheumatoid arthritis. Chen D, Zeng S, Huang M, Xu H, Liang L, Yang X. J Cell Mol Med 21 781-790 (2017)
  162. Celastrol attenuates bone erosion in collagen-Induced arthritis mice and inhibits osteoclast differentiation and function in RANKL-induced RAW264.7. Gan K, Xu L, Feng X, Zhang Q, Wang F, Zhang M, Tan W. Int Immunopharmacol 24 239-246 (2015)
  163. Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket. Frazzetto M, Suphioglu C, Zhu J, Schmidt-Kittler O, Jennings IG, Cranmer SL, Jackson SP, Kinzler KW, Vogelstein B, Thompson PE. Biochem J 414 383-390 (2008)
  164. Epigallocatechin-3-gallate ameliorates autoimmune arthritis by reciprocal regulation of T helper-17 regulatory T cells and inhibition of osteoclastogenesis by inhibiting STAT3 signaling. Lee SY, Jung YO, Ryu JG, Oh HJ, Son HJ, Lee SH, Kwon JE, Kim EK, Park MK, Park SH, Kim HY, Cho ML. J Leukoc Biol 100 559-568 (2016)
  165. PI3Kgamma (PI3Kgamma) is essential for efficient induction of CXCR3 on activated T cells. Barbi J, Cummings HE, Lu B, Oghumu S, Rückle T, Rommel C, Lafuse W, Whitacre CC, Satoskar AR. Blood 112 3048-3051 (2008)
  166. Phospholipase D1 has a pivotal role in interleukin-1β-driven chronic autoimmune arthritis through regulation of NF-κB, hypoxia-inducible factor 1α, and FoxO3a. Kang DW, Park MK, Oh HJ, Lee DG, Park SH, Choi KY, Cho ML, Min do S. Mol Cell Biol 33 2760-2772 (2013)
  167. Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus. Ferguson MS, Chard Dunmall LS, Gangeswaran R, Marelli G, Tysome JR, Burns E, Whitehead MA, Aksoy E, Alusi G, Hiley C, Ahmed J, Vanhaesebroeck B, Lemoine NR, Wang Y. Mol Ther 28 1263-1275 (2020)
  168. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias. Gusscott S, Jenkins CE, Lam SH, Giambra V, Pollak M, Weng AP. PLoS One 11 e0161158 (2016)
  169. Identification of upregulated phosphoinositide 3-kinase γ as a target to suppress breast cancer cell migration and invasion. Xie Y, Abel PW, Kirui JK, Deng C, Sharma P, Wolff DW, Toews ML, Tu Y. Biochem Pharmacol 85 1454-1462 (2013)
  170. Inhibition of PI3Kδ reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse. Suárez-Fueyo A, Rojas JM, Cariaga AE, García E, Steiner BH, Barber DF, Puri KD, Carrera AC. J Immunol 193 544-554 (2014)
  171. Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice. Toyama S, Tamura N, Haruta K, Karakida T, Mori S, Watanabe T, Yamori T, Takasaki Y. Arthritis Res Ther 12 R92 (2010)
  172. PI3Kγ deficiency delays the onset of experimental autoimmune encephalomyelitis and ameliorates its clinical outcome. Berod L, Heinemann C, Heink S, Escher A, Stadelmann C, Drube S, Wetzker R, Norgauer J, Kamradt T. Eur J Immunol 41 833-844 (2011)
  173. Phosphoinositide 3-kinase-gamma expression is upregulated in brain microglia and contributes to ischemia-induced microglial activation in acute experimental stroke. Jin R, Yu S, Song Z, Quillin JW, Deasis DP, Penninger JM, Nanda A, Granger DN, Li G. Biochem Biophys Res Commun 399 458-464 (2010)
  174. Remodeling of VE-cadherin junctions by the human herpes virus 8 G-protein coupled receptor. Dwyer J, Le Guelte A, Galan Moya EM, Sumbal M, Carlotti A, Douguet L, Gutkind JS, Grange PA, Dupin N, Gavard J, Gavard J. Oncogene 30 190-200 (2011)
  175. The novel therapeutic effect of phosphoinositide 3-kinase-γ inhibitor AS605240 in autoimmune diabetes. Azzi J, Moore RF, Elyaman W, Mounayar M, El Haddad N, Yang S, Jurewicz M, Takakura A, Petrelli A, Fiorina P, Ruckle T, Abdi R. Diabetes 61 1509-1518 (2012)
  176. Inhibition of the PI3K/AKT pathway reduces tumor necrosis factor-alpha production in the cellular response to wear particles in vitro. Huang JB, Ding Y, Huang DS, Liang AJ, Zeng WK, Zeng ZP, Qin CQ, Barden B. Artif Organs 37 298-307 (2013)
  177. Irreversible platelet activation requires protease-activated receptor 1-mediated signaling to phosphatidylinositol phosphates. Holinstat M, Preininger AM, Milne SB, Hudson WJ, Brown HA, Hamm HE. Mol Pharmacol 76 301-313 (2009)
  178. Phosphoinositide 3-kinase gamma regulates airway smooth muscle contraction by modulating calcium oscillations. Jiang H, Abel PW, Toews ML, Deng C, Casale TB, Xie Y, Tu Y. J Pharmacol Exp Ther 334 703-709 (2010)
  179. Pulmonary-derived phosphoinositide 3-kinase gamma (PI3Kγ) contributes to ventilator-induced lung injury and edema. Fanelli V, Puntorieri V, Assenzio B, Martin EL, Elia V, Bosco M, Delsedime L, Del Sorbo L, Ferrari A, Italiano S, Ghigo A, Slutsky AS, Hirsch E, Ranieri VM. Intensive Care Med 36 1935-1945 (2010)
  180. RIPK1 inhibition attenuates experimental autoimmune arthritis via suppression of osteoclastogenesis. Jhun J, Lee SH, Kim SY, Ryu J, Kwon JY, Na HS, Jung K, Moon SJ, Cho ML, Min JK. J Transl Med 17 84 (2019)
  181. Severe neutrophil-dominated inflammation and enhanced myelopoiesis in IL-33-overexpressing CMV/IL33 mice. Talabot-Ayer D, Martin P, Vesin C, Seemayer CA, Vigne S, Gabay C, Palmer G. J Immunol 194 750-760 (2015)
  182. Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110alpha inhibitors. Kendall JD, Rewcastle GW, Frederick R, Mawson C, Denny WA, Marshall ES, Baguley BC, Chaussade C, Jackson SP, Shepherd PR. Bioorg Med Chem 15 7677-7687 (2007)
  183. Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies. Haselmayer P, Camps M, Muzerelle M, El Bawab S, Waltzinger C, Bruns L, Abla N, Polokoff MA, Jond-Necand C, Gaudet M, Benoit A, Bertschy Meier D, Martin C, Gretener D, Lombardi MS, Grenningloh R, Ladel C, Petersen JS, Gaillard P, Ji H. Front Immunol 5 233 (2014)
  184. Kaempferol targeting on the fibroblast growth factor receptor 3-ribosomal S6 kinase 2 signaling axis prevents the development of rheumatoid arthritis. Lee CJ, Moon SJ, Jeong JH, Lee S, Lee MH, Yoo SM, Lee HS, Kang HC, Lee JY, Lee WS, Lee HJ, Kim EK, Jhun JY, Cho ML, Min JK, Cho YY. Cell Death Dis 9 401 (2018)
  185. PTEN ameliorates autoimmune arthritis through down-regulating STAT3 activation with reciprocal balance of Th17 and Tregs. Lee SH, Park JS, Byun JK, Jhun J, Jung K, Seo HB, Moon YM, Kim HY, Park SH, Cho ML. Sci Rep 6 34617 (2016)
  186. PTEN negatively regulates engulfment of apoptotic cells by modulating activation of Rac GTPase. Mondal S, Ghosh-Roy S, Loison F, Li Y, Jia Y, Harris C, Williams DA, Luo HR. J Immunol 187 5783-5794 (2011)
  187. Grape seed proanthocyanidin extract-mediated regulation of STAT3 proteins contributes to Treg differentiation and attenuates inflammation in a murine model of obesity-associated arthritis. Jhun JY, Moon SJ, Yoon BY, Byun JK, Kim EK, Yang EJ, Ju JH, Hong YS, Min JK, Park SH, Kim HY, Cho ML. PLoS One 8 e78843 (2013)
  188. Inhibition of DNM1L and mitochondrial fission attenuates inflammatory response in fibroblast-like synoviocytes of rheumatoid arthritis. Wang X, Chen Z, Fan X, Li W, Qu J, Dong C, Wang Z, Ji Z, Li Y. J Cell Mol Med 24 1516-1528 (2020)
  189. Leptin Mediates In Vivo Neutrophil Migration: Involvement of Tumor Necrosis Factor-Alpha and CXCL1. Souza-Almeida G, D'Avila H, Almeida PE, Luna-Gomes T, Liechocki S, Walzog B, Hepper I, Castro-Faria-Neto HC, Bozza PT, Bandeira-Melo C, Maya-Monteiro CM. Front Immunol 9 111 (2018)
  190. Magnetically retainable microparticles for drug delivery to the joint: efficacy studies in an antigen-induced arthritis model in mice. Butoescu N, Seemayer CA, Palmer G, Guerne PA, Gabay C, Doelker E, Jordan O. Arthritis Res Ther 11 R72 (2009)
  191. Neutrophil Immunomodulatory Activity of Natural Organosulfur Compounds. Schepetkin IA, Kirpotina LN, Khlebnikov AI, Balasubramanian N, Quinn MT. Molecules 24 E1809 (2019)
  192. Pharmacologic inhibition of phosphoinositide 3-kinase gamma (PI3Kγ) promotes infarct resorption and prevents adverse cardiac remodeling after myocardial infarction in mice. Seropian IM, Abbate A, Toldo S, Harrington J, Smithson L, Ockaili R, Mezzaroma E, Damilano F, Hirsch E, Van Tassell BW. J Cardiovasc Pharmacol 56 651-658 (2010)
  193. The mechanisms of up-regulation of dendritic cell activity by oxidative stress. Batal I, Azzi J, Mounayar M, Abdoli R, Moore R, Lee JY, Rosetti F, Wang C, Fiorina P, Sackstein R, Ichimura T, Abdi R. J Leukoc Biol 96 283-293 (2014)
  194. Amelioration of autoimmune arthritis by adoptive transfer of Foxp3-expressing regulatory B cells is associated with the Treg/Th17 cell balance. Park MK, Jung YO, Lee SY, Lee SH, Heo YJ, Kim EK, Oh HJ, Moon YM, Son HJ, Park MJ, Park SH, Kim HY, Cho ML, Min JK. J Transl Med 14 191 (2016)
  195. GRPR/PI3Kγ: Partners in Central Transmission of Itch. Pereira PJ, Machado GD, Danesi GM, Canevese FF, Reddy VB, Pereira TC, Bogo MR, Cheng YC, Laedermann C, Talbot S, Lerner EA, Campos MM. J Neurosci 35 16272-16281 (2015)
  196. MicroRNA-204-3p inhibits lipopolysaccharide-induced cytokines in familial Mediterranean fever via the phosphoinositide 3-kinase γ pathway. Koga T, Migita K, Sato T, Sato S, Umeda M, Nonaka F, Fukui S, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Ueki Y, Masumoto J, Agematsu K, Yachie A, Yoshiura KI, Eguchi K, Kawakami A. Rheumatology (Oxford) 57 718-726 (2018)
  197. Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis. Boyle DL, Kim HR, Topolewski K, Bartok B, Firestein GS. J Pharmacol Exp Ther 348 271-280 (2014)
  198. Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. Evangelisti C, Cappellini A, Oliveira M, Fragoso R, Barata JT, Bertaina A, Locatelli F, Simioni C, Neri LM, Chiarini F, Lonetti A, Buontempo F, Orsini E, Pession A, Manzoli L, Martelli AM, Evangelisti C. J Cell Physiol 233 1796-1811 (2018)
  199. Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ. Uehara M, McGrath MM, Ohori S, Solhjou Z, Banouni N, Routray S, Evans C, DiNitto JP, Elkhal A, Turka LA, Strom TB, Tullius SG, Winkler DG, Azzi J, Abdi R. Nat Commun 8 951 (2017)
  200. Synovial fibroblast-derived exosomal microRNA-106b suppresses chondrocyte proliferation and migration in rheumatoid arthritis via down-regulation of PDK4. Liu D, Fang Y, Rao Y, Tan W, Zhou W, Wu X, Zhang C, Zhang Y, Liu Y, Sunagawa M, Hisamitsu T, Li G. J Mol Med (Berl) 98 409-423 (2020)
  201. An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. De P, Dey N, Terakedis B, Bergsagel PL, Li ZH, Mahadevan D, Garlich JR, Trudel S, Makale MT, Durden DL. Cancer Chemother Pharmacol 71 867-881 (2013)
  202. META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis. Konda VR, Desai A, Darland G, Bland JS, Tripp ML. Arthritis Rheum 62 1683-1692 (2010)
  203. Phosphatase and tensin homolog (PTEN) in antigen-presenting cells controls Th17-mediated autoimmune arthritis. Blüml S, Sahin E, Saferding V, Goncalves-Alves E, Hainzl E, Niederreiter B, Hladik A, Lohmeyer T, Brunner JS, Bonelli M, Koenders MI, van den Berg WB, Superti-Furga G, Smolen JS, Schabbauer G, Redlich K. Arthritis Res Ther 17 230 (2015)
  204. Phosphoinositide-3-kinase (PI3K) inhibitors: identification of new scaffolds using virtual screening. Frédérick R, Mawson C, Kendall JD, Chaussade C, Rewcastle GW, Shepherd PR, Denny WA. Bioorg Med Chem Lett 19 5842-5847 (2009)
  205. Quantification of bone changes in a collagen-induced arthritis mouse model by reconstructed three dimensional micro-CT. Yang S, Hollister AM, Orchard EA, Chaudhery SI, Ostanin DV, Lokitz SJ, Mathis JM. Biol Proced Online 15 8 (2013)
  206. Rebamipide attenuates autoimmune arthritis severity in SKG mice via regulation of B cell and antibody production. Byun JK, Moon SJ, Jhun JY, Kim EK, Park JS, Youn J, Min JK, Park SH, Kim HY, Cho ML. Clin Exp Immunol 178 9-19 (2014)
  207. Schistosoma japonicum cystatin attenuates murine collagen-induced arthritis. Liu F, Cheng W, Pappoe F, Hu X, Wen H, Luo Q, Wang S, Deng F, Xie Y, Xu Y, Shen J. Parasitol Res 115 3795-3806 (2016)
  208. TNFR2/14-3-3ε signaling complex instructs macrophage plasticity in inflammation and autoimmunity. Fu W, Hu W, Yi YS, Hettinghouse A, Sun G, Bi Y, He W, Zhang L, Gao G, Liu J, Toyo-Oka K, Xiao G, Solit DB, Loke P, Liu CJ. J Clin Invest 131 144016 (2021)
  209. 11β-Hydroxysteroid dehydrogenase 1 inhibition attenuates collagen-induced arthritis. Zhang L, Dong Y, Zou F, Wu M, Fan C, Ding Y. Int Immunopharmacol 17 489-494 (2013)
  210. Cyclic GMP-AMP Synthase Is Required for Cell Proliferation and Inflammatory Responses in Rheumatoid Arthritis Synoviocytes. Wang Y, Su GH, Zhang F, Chu JX, Wang YS. Mediators Inflamm 2015 192329 (2015)
  211. Divergent roles of Smad3 and PI3-kinase in murine adriamycin nephropathy indicate distinct mechanisms of proteinuria and fibrogenesis. Finer G, Schnaper HW, Kanwar YS, Liang X, Lin HY, Hayashida T. Kidney Int 82 525-536 (2012)
  212. Inhibition of phosphatidylinositol-3 kinase γ reduces pruriceptive, inflammatory, and nociceptive responses induced by trypsin in mice. Pereira PJS, Lazarotto LF, Leal PC, Lopes TG, Morrone FB, Campos MM. Pain 152 2861-2869 (2011)
  213. Inhibition of phosphoinositide 3-kinase γ attenuates inflammation, obesity, and cardiovascular risk factors. Wymann MP, Solinas G. Ann N Y Acad Sci 1280 44-47 (2013)
  214. Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats. Haruta K, Mori S, Tamura N, Sasaki A, Nagamine M, Yaguchi S, Kamachi F, Enami J, Kobayashi S, Yamori T, Takasaki Y. Inflamm Res 61 551-562 (2012)
  215. Insights into the PI3-K-PKB-mTOR signalling pathway from small molecules. Gunn RM, Hailes HC. J Chem Biol 1 49-62 (2008)
  216. Petri Net computational modelling of Langerhans cell Interferon Regulatory Factor Network predicts their role in T cell activation. Polak ME, Ung CY, Masapust J, Freeman TC, Ardern-Jones MR. Sci Rep 7 668 (2017)
  217. The effect of the cholinergic anti-inflammatory pathway on collagen-induced arthritis involves the modulation of dendritic cell differentiation. Liu D, Li T, Luo H, Zuo X, Liu S, Wu S. Arthritis Res Ther 20 263 (2018)
  218. Treatment of IL-21R-Fc control autoimmune arthritis via suppression of STAT3 signal pathway mediated regulation of the Th17/Treg balance and plasma B cells. Ryu JG, Lee J, Kim EK, Seo HB, Park JS, Lee SY, Moon YM, Yoo SH, Park YW, Park SH, Cho ML, Kim HY. Immunol Lett 163 143-150 (2015)
  219. p110γ deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity. Torres C, Mancinelli G, Cordoba-Chacon J, Viswakarma N, Castellanos K, Grimaldo S, Kumar S, Principe D, Dorman MJ, McKinney R, Hirsch E, Dawson D, Munshi HG, Rana A, Grippo PJ. Proc Natl Acad Sci U S A 116 14724-14733 (2019)
  220. Identification of a novel microRNA-141-3p/Forkhead box C1/β-catenin axis associated with rheumatoid arthritis synovial fibroblast function in vivo and in vitro. Wang J, Wang Y, Zhang H, Chang J, Lu M, Gao W, Liu W, Li Y, Yin L, Wang X, Wang Y, Gao M, Yin Z. Theranostics 10 5412-5434 (2020)
  221. Immune-mediated experimental arthritis in IL-33 deficient mice. Talabot-Ayer D, Martin P, Seemayer CA, Vigne S, Lamacchia C, Finckh A, Saiji E, Gabay C, Palmer G. Cytokine 69 68-74 (2014)
  222. Interleukin-27 suppresses osteoclastogenesis via induction of interferon-γ. Park JS, Jung YO, Oh HJ, Park SJ, Heo YJ, Kang CM, Kwok SK, Ju JH, Park KS, Cho ML, Sung YC, Park SH, Kim HY. Immunology 137 326-335 (2012)
  223. Loss of phosphoinositide 3-kinase gamma decreases migration and activation of phagocytes but not T cell activation in antigen-induced arthritis. Gruen M, Rose C, König C, Gajda M, Wetzker R, Bräuer R. BMC Musculoskelet Disord 11 63 (2010)
  224. Modulation of phosphorylation of tocopherol and phosphatidylinositol by hTAP1/SEC14L2-mediated lipid exchange. Zingg JM, Libinaki R, Meydani M, Azzi A. PLoS One 9 e101550 (2014)
  225. PI3Kγ controls leukocyte recruitment, tissue injury, and lethality in a model of graft-versus-host disease in mice. Castor MG, Rezende BM, Bernardes PT, Vieira AT, Vieira EL, Arantes RM, Souza DG, Silva TA, Teixeira MM, Pinho V. J Leukoc Biol 89 955-964 (2011)
  226. Regulation of PI3K/Akt signaling by N-desmethylclozapine through activation of δ-opioid receptor. Olianas MC, Dedoni S, Onali P. Eur J Pharmacol 660 341-350 (2011)
  227. Role of host cell polarity and leading edge properties in Pseudomonas type III secretion. Bridge DR, Novotny MJ, Moore ER, Olson JC. Microbiology (Reading) 156 356-373 (2010)
  228. Silencing the expression of Ras family GTPase homologues decreases inflammation and joint destruction in experimental arthritis. de Launay D, Vreijling J, Hartkamp LM, Karpus ON, Abreu JR, van Maanen MA, Sanders ME, Grabiec AM, Hamann J, Ørum H, Vervoordeldonk MJ, Fluiter K, Tak PP, Reedquist KA. Am J Pathol 177 3010-3024 (2010)
  229. Structure of the phosphoinositide 3-kinase (PI3K) p110γ-p101 complex reveals molecular mechanism of GPCR activation. Rathinaswamy MK, Dalwadi U, Fleming KD, Adams C, Stariha JTB, Pardon E, Baek M, Vadas O, DiMaio F, Steyaert J, Hansen SD, Yip CK, Burke JE. Sci Adv 7 eabj4282 (2021)
  230. Adoptive transfer of all-trans-retinal-induced regulatory T cells ameliorates experimental autoimmune arthritis in an interferon-gamma knockout model. Jeon EJ, Yoon BY, Lim JY, Oh HJ, Park HS, Park MJ, Lim MA, Park MK, Kim KW, Cho ML, Cho SG. Autoimmunity 45 460-469 (2012)
  231. Asthma: beyond corticosteroid treatment. Marandi Y, Farahi N, Hashjin GS. Arch Med Sci 9 521-526 (2013)
  232. Differential regulation of cytokine production by PI3Kdelta in human monocytes upon acute and chronic inflammatory conditions. Molnarfi N, Brandt KJ, Gruaz L, Dayer JM, Burger D. Mol Immunol 45 3419-3427 (2008)
  233. Genetic ablation of PI3Kγ results in defective IL-17RA signalling in T lymphocytes and increased IL-17 levels. Harris SJ, Ciuclan L, Finan PM, Wymann MP, Walker C, Westwick J, Ward SG, Thomas MJ. Eur J Immunol 42 3394-3404 (2012)
  234. Halofuginone inhibits TNF-α-induced the migration and proliferation of fibroblast-like synoviocytes from rheumatoid arthritis patients. Zeng S, Wang K, Huang M, Qiu Q, Xiao Y, Shi M, Zou Y, Yang X, Xu H, Liang L. Int Immunopharmacol 43 187-194 (2017)
  235. Multiple phosphatidylinositol 3-kinases regulate vaccinia virus morphogenesis. McNulty S, Bornmann W, Schriewer J, Werner C, Smith SK, Olson VA, Damon IK, Buller RM, Heuser J, Kalman D. PLoS One 5 e10884 (2010)
  236. PI3Kγ Is Critical for Dendritic Cell-Mediated CD8+ T Cell Priming and Viral Clearance during Influenza Virus Infection. Nobs SP, Schneider C, Heer AK, Huotari J, Helenius A, Kopf M. PLoS Pathog 12 e1005508 (2016)
  237. Phosphoinositide 3-kinase gamma inhibitor ameliorates concanavalin A-induced hepatic injury in mice. Wang ZL, Wu XH, Song LF, Wang YS, Hu XH, Luo YF, Chen ZZ, Ke J, Peng XD, He CM, Zhang W, Chen LJ, Wei YQ. Biochem Biophys Res Commun 386 569-574 (2009)
  238. Phosphoinositide 3-kinase gamma required for lipopolysaccharide-induced transepithelial neutrophil trafficking in the lung. Reutershan J, Saprito MS, Wu D, Rückle T, Ley K. Eur Respir J 35 1137-1147 (2010)
  239. Role of phosphoinositide 3-kinase IA (PI3K-IA) activation in cardioprotection induced by ouabain preconditioning. Duan Q, Madan ND, Wu J, Kalisz J, Doshi KY, Haldar SM, Liu L, Pierre SV. J Mol Cell Cardiol 80 114-125 (2015)
  240. Ssu72 attenuates autoimmune arthritis via targeting of STAT3 signaling and Th17 activation. Lee SH, Kim EK, Kwon JE, Lee JK, Lee D, Kim SY, Seo HB, Na HS, Jung K, Kwok SK, Lee CW, Park SH, Cho ML. Sci Rep 7 5506 (2017)
  241. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. Pillinger G, Loughran NV, Piddock RE, Shafat MS, Zaitseva L, Abdul-Aziz A, Lawes MJ, Bowles KM, Rushworth SA. Oncotarget 7 39784-39795 (2016)
  242. The effect of pharmacological PI3Kγ inhibitor on eotaxin-induced human eosinophil functions. Saito Y, Takeda M, Nishikawa J, Konno Y, Tamaki M, Itoga M, Kobayashi Y, Moritoki Y, Ito W, Chihara J, Ueki S. Pulm Pharmacol Ther 27 164-169 (2014)
  243. δ-Opioid receptors stimulate GLUT1-mediated glucose uptake through Src- and IGF-1 receptor-dependent activation of PI3-kinase signalling in CHO cells. Olianas MC, Dedoni S, Onali P. Br J Pharmacol 163 624-637 (2011)
  244. A Combination with Probiotic Complex, Zinc, and Coenzyme Q10 Attenuates Autoimmune Arthritis by Regulation of Th17/Treg Balance. Lee SY, Lee SH, Jhun J, Seo HB, Jung KA, Yang CW, Park SH, Cho ML. J Med Food 21 39-46 (2018)
  245. CARD11 blockade suppresses murine collagen-induced arthritis via inhibiting CARD11/Bcl10 assembly and T helper type 17 response. Wang H, Zhao J, Zhang H, Huang Y, Wang S, Tu Q, Yang N. Clin Exp Immunol 176 238-245 (2014)
  246. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy. Ksionda O, Mues M, Wandler AM, Donker L, Tenhagen M, Jun J, Ducker GS, Matlawska-Wasowska K, Shannon K, Shokat KM, Roose JP. PLoS One 13 e0193849 (2018)
  247. Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors. Hoegenauer K, Soldermann N, Stauffer F, Furet P, Graveleau N, Smith AB, Hebach C, Hollingworth GJ, Lewis I, Gutmann S, Rummel G, Knapp M, Wolf RM, Blanz J, Feifel R, Burkhart C, Zécri F. ACS Med Chem Lett 7 762-767 (2016)
  248. Insulin secretion induced by glucose-dependent insulinotropic polypeptide requires phosphatidylinositol 3-kinase γ in rodent and human β-cells. Kolic J, Spigelman AF, Smith AM, Manning Fox JE, MacDonald PE. J Biol Chem 289 32109-32120 (2014)
  249. MicroRNA-21 from bone marrow mesenchymal stem cell-derived extracellular vesicles targets TET1 to suppress KLF4 and alleviate rheumatoid arthritis. Li GQ, Fang YX, Liu Y, Meng FR, Wu X, Zhang CW, Zhang Y, Liu YQ, Liu D. Ther Adv Chronic Dis 12 20406223211007369 (2021)
  250. PI3Kγ inhibition alleviates symptoms and increases axon number in experimental autoimmune encephalomyelitis mice. Li H, Park D, Abdul-Muneer PM, Xu B, Wang H, Xing B, Wu D, Li S. Neuroscience 253 89-99 (2013)
  251. Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities. Blunt MD, Ward SG. Front Immunol 3 226 (2012)
  252. Structural analysis of PI3-kinase isoforms: identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors. Zvelebil MJ, Waterfield MD, Shuttleworth SJ. Arch Biochem Biophys 477 404-410 (2008)
  253. A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis. Cheng CP, Huang HS, Hsu YC, Sheu MJ, Chang DM. J Clin Immunol 32 762-777 (2012)
  254. Canonical PI3Kγ signaling in myeloid cells restricts Trypanosoma cruzi infection and dampens chagasic myocarditis. Silva MC, Davoli-Ferreira M, Medina TS, Sesti-Costa R, Silva GK, Lopes CD, Cardozo LE, Gava FN, Lyroni K, Dias FC, Frade AF, Baron M, Nakaya HI, Figueiredo F, Alves-Filho JC, Cunha FQ, Tsatsanis C, Chevillard C, Cunha-Neto E, Hirsch E, Silva JS, Cunha TM. Nat Commun 9 1513 (2018)
  255. Different PI 3-kinase inhibitors have distinct effects on endothelial permeability and leukocyte transmigration. Cain RJ, Vanhaesebroeck B, Ridley AJ. Int J Biochem Cell Biol 44 1929-1936 (2012)
  256. Discovery and Structure-Activity Relationship Study of (Z)-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. Manz TD, Sivakumaren SC, Ferguson FM, Zhang T, Yasgar A, Seo HS, Ficarro SB, Card JD, Shim H, Miduturu CV, Simeonov A, Shen M, Marto JA, Dhe-Paganon S, Hall MD, Cantley LC, Gray NS. J Med Chem 63 4880-4895 (2020)
  257. Liposome/gold hybrid nanoparticle encoded with CoQ10 (LGNP-CoQ10) suppressed rheumatoid arthritis via STAT3/Th17 targeting. Jhun J, Moon J, Ryu J, Shin Y, Lee S, Cho KH, Kang T, Cho ML, Park SH. PLoS One 15 e0241080 (2020)
  258. PI3Kγ (Phosphoinositide 3-Kinase-γ) Inhibition Attenuates Tissue-Type Plasminogen Activator-Induced Brain Hemorrhage and Improves Microvascular Patency After Embolic Stroke. Jin R, Xiao AY, Li J, Wang M, Li G. Hypertension 73 206-216 (2019)
  259. PI3Kγ drives priming and survival of autoreactive CD4(+) T cells during experimental autoimmune encephalomyelitis. Comerford I, Litchfield W, Kara E, McColl SR. PLoS One 7 e45095 (2012)
  260. Pharmacologic P2X purinergic receptor antagonism in the treatment of collagen-induced arthritis. Ardissone V, Radaelli E, Zaratin P, Ardizzone M, Ladel C, Gattorno M, Martini A, Grassi F, Traggiai E. Arthritis Rheum 63 3323-3332 (2011)
  261. Pharmacologic profiling of phosphoinositide 3-kinase inhibitors as mitigators of ionizing radiation-induced cell death. Lazo JS, Sharlow ER, Epperly MW, Lira A, Leimgruber S, Skoda EM, Wipf P, Greenberger JS. J Pharmacol Exp Ther 347 669-680 (2013)
  262. Targeting PI3K in neuroblastoma. Spitzenberg V, König C, Ulm S, Marone R, Röpke L, Müller JP, Grün M, Bauer R, Rubio I, Wymann MP, Voigt A, Wetzker R. J Cancer Res Clin Oncol 136 1881-1890 (2010)
  263. The dilemma of anticancer therapy: tumor-specific versus immune effects. Zitvogel L, Kroemer G. Blood 112 4364-4365 (2008)
  264. A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth. Wang X, Li JP, Yang Y, Ding J, Meng LH. Acta Pharmacol Sin 34 1201-1207 (2013)
  265. Abrogation of antibody-induced arthritis in mice by a self-activating viridin prodrug and association with impaired neutrophil and endothelial cell function. Stangenberg L, Ellson C, Cortez-Retamozo V, Ortiz-Lopez A, Yuan H, Blois J, Smith RA, Yaffe MB, Weissleder R, Benoist C, Mathis D, Josephson L, Mahmood U. Arthritis Rheum 60 2314-2324 (2009)
  266. Disease-related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors. Rathinaswamy MK, Gaieb Z, Fleming KD, Borsari C, Harris NJ, Moeller BE, Wymann MP, Amaro RE, Burke JE. Elife 10 e64691 (2021)
  267. Exosomal microRNA-140-3p from human umbilical cord mesenchymal stem cells attenuates joint injury of rats with rheumatoid arthritis by silencing SGK1. Huang Y, Chen L, Chen D, Fan P, Yu H. Mol Med 28 36 (2022)
  268. GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis. Gobert RP, van den Eijnden M, Szyndralewiez C, Jorand-Lebrun C, Swinnen D, Chen L, Gillieron C, Pixley F, Juillard P, Gerber P, Johnson-Léger C, Halazy S, Camps M, Bombrun A, Shipp M, Vitte PA, Ardissone V, Ferrandi C, Perrin D, Rommel C, Hooft van Huijsduijnen R. J Biol Chem 284 11385-11395 (2009)
  269. Ginkgolide B attenuates collagen-induced rheumatoid arthritis and regulates fibroblast-like synoviocytes-mediated apoptosis and inflammation. Xie C, Jiang J, Liu J, Yuan G, Zhao Z. Ann Transl Med 8 1497 (2020)
  270. L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ Pinson JA, Zheng Z, Miller MS, Chalmers DK, Jennings IG, Thompson PE. ACS Med Chem Lett 4 206-210 (2013)
  271. Comment Modulating autoimmunity: pick your PI3 kinase. Ohashi PS, Woodgett JR. Nat Med 11 924-925 (2005)
  272. PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. Ultimo S, Simioni C, Martelli AM, Zauli G, Evangelisti C, Celeghini C, McCubrey JA, Marisi G, Ulivi P, Capitani S, Neri LM. Oncotarget 8 23213-23227 (2017)
  273. PI3Kγ (Phosphoinositide 3-Kinase γ) Regulates Vascular Smooth Muscle Cell Phenotypic Modulation and Neointimal Formation Through CREB (Cyclic AMP-Response Element Binding Protein)/YAP (Yes-Associated Protein) Signaling. Yu Q, Li W, Jin R, Yu S, Xie D, Zheng X, Zhong W, Cheng X, Hu S, Li M, Zheng Q, Li G, Song Z. Arterioscler Thromb Vasc Biol 39 e91-e105 (2019)
  274. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. Sahin I, Azab F, Mishima Y, Moschetta M, Tsang B, Glavey SV, Manier S, Zhang Y, Sacco A, Roccaro AM, Azab AK, Ghobrial IM. Am J Hematol 89 1030-1036 (2014)
  275. The PGE2-induced inhibition of the PLD activation pathway stimulated by fMLP in human neutrophils is mediated by PKA at the PI3-Kgamma level. Burelout C, Thibault N, Harbour D, Naccache PH, Bourgoin SG. Biochem Pharmacol 74 730-741 (2007)
  276. Up-regulation of the phosphoinositide 3-kinase pathway in human lamina propria T lymphocytes. Braunstein J, Autschbach F, Giese T, Lasitschka F, Heidtmann A, Sido B, Funke B, Reiser C, Schröder AJ, Nebl G, Samstag Y, Meuer SC. Clin Exp Immunol 151 496-504 (2008)
  277. Antigenic challenge in the etiology of autoimmune disease in women. Rogers MA, Levine DA, Blumberg N, Fisher GG, Kabeto M, Langa KM. J Autoimmun 38 J97-J102 (2012)
  278. Boldine isolated from Litsea cubeba inhibits bone resorption by suppressing the osteoclast differentiation in collagen-induced arthritis. Zhao H, Xu H, Qiao S, Lu C, Wang G, Liu M, Guo B, Tan Y, Ju D, Xiao C. Int Immunopharmacol 51 114-123 (2017)
  279. Dishevelled2 promotes apoptosis and inhibits inflammatory cytokine secretion in rheumatoid arthritis fibroblast-like synoviocytes through crosstalk with the NF-κB pathway. Liu XZ, Fan J, Qi K, Liu SP, Xu WD, Gao Y, Gu XD, Li J, Bai CG, Shi YQ, Zhang LL, Zhao DB. Oncotarget 8 12649-12663 (2017)
  280. Endothelial PI 3-kinase activity regulates lymphocyte diapedesis. Nakhaei-Nejad M, Hussain AM, Zhang QX, Murray AG. Am J Physiol Heart Circ Physiol 293 H3608-16 (2007)
  281. Genetic Deletion and Pharmacological Inhibition of PI3K γ Reduces Neutrophilic Airway Inflammation and Lung Damage in Mice with Cystic Fibrosis-Like Lung Disease. Galluzzo M, Ciraolo E, Lucattelli M, Hoxha E, Ulrich M, Campa CC, Lungarella G, Doring G, Zhou-Suckow Z, Mall M, Hirsch E, De Rose V. Mediators Inflamm 2015 545417 (2015)
  282. Niacin activates the PI3K/Akt cascade via PKC- and EGFR-transactivation-dependent pathways through hydroxyl-carboxylic acid receptor 2. Sun H, Li G, Zhang W, Zhou Q, Yu Y, Shi Y, Offermanns S, Lu J, Zhou N. PLoS One 9 e112310 (2014)
  283. PI3Kγ Regulatory Protein p84 Determines Mast Cell Sensitivity to Ras Inhibition-Moving Towards Cell Specific PI3K Targeting? Jin JR, Gogvadze E, Xavier AR, Bohnacker T, Voelzmann J, Wymann MP. Front Immunol 11 585070 (2020)
  284. Phosphoinositide 3-kinase γ deficiency attenuates kidney injury and fibrosis in angiotensin II-induced hypertension. An C, Wen J, Hu Z, Mitch WE, Wang Y. Nephrol Dial Transplant 35 1491-1500 (2020)
  285. Role of phosphatidylinositol-3 kinase-gamma in the actions of glucagon-like peptide-2 on the murine small intestine. Anini Y, Izzo A, Oudit GY, Backx PH, Brubaker PL. Am J Physiol Endocrinol Metab 292 E1599-606 (2007)
  286. Semi-synthesis and anti-proliferative activity evaluation of novel analogues of Honokiol. Luo Y, Xu Y, Chen L, Hu J, Peng C, Xie D, Shi J, Huang W, Xu G, Peng M, Han J, Li R, Yang S, Wei Y. Bioorg Med Chem Lett 19 4702-4705 (2009)
  287. Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines. Juvin V, Malek M, Anderson KE, Dion C, Chessa T, Lecureuil C, Ferguson GJ, Cosulich S, Hawkins PT, Stephens LR. PLoS One 8 e75045 (2013)
  288. Taurine chloramine inhibits osteoclastogenesis and splenic lymphocyte proliferation in mice with collagen-induced arthritis. Wang Y, Cha YN, Kim KS, Kim C. Eur J Pharmacol 668 325-330 (2011)
  289. α-Tocopheryl Phosphate Induces VEGF Expression via CD36/PI3Kγ in THP-1 Monocytes. Zingg JM, Azzi A, Meydani M. J Cell Biochem 118 1855-1867 (2017)
  290. IL-12p40 Homodimer Ameliorates Experimental Autoimmune Arthritis. Lee SY, Jung YO, Kim DJ, Kang CM, Moon YM, Heo YJ, Oh HJ, Park SJ, Yang SH, Kwok SK, Ju JH, Park SH, Sung YC, Kim HY, Cho ML. J Immunol 195 3001-3010 (2015)
  291. PI3Kγ Inhibition Protects Against Diabetic Cardiomyopathy in Mice. Maffei A, Cifelli G, Carnevale R, Iacobucci R, Pallante F, Fardella V, Fardella S, Hirsch E, Lembo G, Carnevale D. Rev Esp Cardiol (Engl Ed) 70 16-24 (2017)
  292. PI3Kγ integrates cAMP and Akt signalling of the μ-opioid receptor. Madishetti S, Schneble N, König C, Hirsch E, Schulz S, Müller JP, Wetzker R. Br J Pharmacol 171 3328-3337 (2014)
  293. Phosphoinositide 3-kinaseγ controls the intracellular localization of CpG to limit DNA-PKcs-dependent IL-10 production in macrophages. Hazeki K, Kametani Y, Murakami H, Uehara M, Ishikawa Y, Nigorikawa K, Takasuga S, Sasaki T, Seya T, Matsumoto M, Hazeki O. PLoS One 6 e26836 (2011)
  294. Synthesis, molecular docking and biological evaluation of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents. Yan R, Zhang ZM, Fang XY, Hu Y, Zhu HL. Bioorg Med Chem 20 1373-1379 (2012)
  295. Targeted delivery of a phosphoinositide 3-kinase γ inhibitor to restore organ function in sepsis. Press AT, Babic P, Hoffmann B, Müller T, Foo W, Hauswald W, Benecke J, Beretta M, Cseresnyés Z, Hoeppener S, Nischang I, Coldewey SM, Gräler MH, Bauer R, Gonnert F, Gaßler N, Wetzker R, Figge MT, Schubert US, Bauer M. EMBO Mol Med 13 e14436 (2021)
  296. Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels. Jeong Y, Jhun J, Lee SY, Na HS, Choi J, Cho KH, Lee SY, Lee AR, Park SJ, You HJ, Kim JW, Park MS, Kwon B, Cho ML, Ji GE, Park SH. Front Immunol 12 736196 (2021)
  297. Ursodeoxycholic acid attenuates experimental autoimmune arthritis by targeting Th17 and inducing pAMPK and transcriptional corepressor SMILE. Lee EJ, Kwon JE, Park MJ, Jung KA, Kim DS, Kim EK, Lee SH, Choi JY, Park SH, Cho ML. Immunol Lett 188 1-8 (2017)
  298. Chondroprotective Effects and Mechanisms of Dextromethorphan: Repurposing Antitussive Medication for Osteoarthritis Treatment. Chen LW, Liu FC, Hung LF, Huang CY, Lien SB, Lin LC, Lai JH, Ho LJ. Int J Mol Sci 19 E825 (2018)
  299. Differential regulation of chemotaxis: role of Gβγ in chemokine receptor-induced cell migration. Kerr JS, Jacques RO, Moyano Cardaba C, Tse T, Sexton D, Mueller A. Cell Signal 25 729-735 (2013)
  300. Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties. Hoegenauer K, Soldermann N, Hebach C, Hollingworth GJ, Lewis I, von Matt A, Smith AB, Wolf RM, Wilcken R, Haasen D, Burkhart C, Zécri F. Bioorg Med Chem Lett 26 5657-5662 (2016)
  301. Inhibition of G Protein βγ Subunit Signaling Abrogates Nephritis in Lupus-Prone Mice. Rangel-Moreno J, To JY, Owen T, Goldman BI, Smrcka AV, Anolik JH. Arthritis Rheumatol 68 2244-2256 (2016)
  302. MG132 protects against renal dysfunction by regulating Akt-mediated inflammation in diabetic nephropathy. Zeng W, Qi W, Mu J, Wei Y, Yang LL, Zhang Q, Wu Q, Tang JY, Feng B. Sci Rep 9 2049 (2019)
  303. Membrane-bound IL-6R is upregulated on Th17 cells and inhibits Treg cell migration by regulating post-translational modification of VASP in autoimmune arthritis. Yan S, Golumba-Nagy V, Kotschenreuther K, Thiele J, Refaian N, Shuya D, Gloyer L, Dittrich-Salamon M, Meyer A, Heindl LM, Kofler DM. Cell Mol Life Sci 79 3 (2021)
  304. Methotrexate-loaded multifunctional nanoparticles with near-infrared irradiation for the treatment of rheumatoid arthritis. Ha YJ, Lee SM, Mun CH, Kim HJ, Bae Y, Lim JH, Park KH, Lee SK, Yoo KH, Park YB. Arthritis Res Ther 22 146 (2020)
  305. Phosphatidylinositol 3-Kinase γ is required for the development of experimental cerebral malaria. Lacerda-Queiroz N, Brant F, Rodrigues DH, Vago JP, Rachid MA, Sousa LP, Teixeira MM, Teixeira AL. PLoS One 10 e0119633 (2015)
  306. Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways. Zwang NA, Zhang R, Germana S, Fan MY, Hastings WD, Cao A, Turka LA. Am J Transplant 16 2624-2638 (2016)
  307. The Inhibition of Phosphoinositide-3 Kinases Induce Resolution of Inflammation in a Gout Model. Galvão I, Queiroz-Junior CM, de Oliveira VLS, Pinho V, Hirsch E, Teixeira MM. Front Pharmacol 9 1505 (2018)
  308. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1. Moon SJ, Kim EK, Jhun JY, Lee HJ, Lee WS, Park SH, Cho ML, Min JK. J Transl Med 15 31 (2017)
  309. α-Ketoglutarate Inhibits Thrombosis and Inflammation by Prolyl Hydroxylase-2 Mediated Inactivation of Phospho-Akt. Shrimali NM, Agarwal S, Kaur S, Bhattacharya S, Bhattacharyya S, Prchal JT, Guchhait P. EBioMedicine 73 103672 (2021)
  310. ACTH treatment promotes murine cardiac allograft acceptance. Zhao J, Jiang L, Uehara M, Banouni N, Al Dulaijan BS, Azzi J, Ichimura T, Li X, Jarolim P, Fiorina P, Tullius SG, Madsen JC, Kasinath V, Abdi R. JCI Insight 6 143385 (2021)
  311. AS252424, a PI3Kγ inhibitor, downregulates inflammatory responsiveness in mouse bone marrow-derived mast cells. Jin M, Zhou Q, Lee E, Dan S, Duan HQ, Kong D. Inflammation 37 1254-1260 (2014)
  312. Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase γ inhibitor for the treatment of inflammatory diseases. Oka Y, Yabuuchi T, Oi T, Kuroda S, Fujii Y, Ohtake H, Inoue T, Wakahara S, Kimura K, Fujita K, Endo M, Taguchi K, Sekiguchi Y. Bioorg Med Chem 21 7578-7583 (2013)
  313. PI3Kγ Deficient NOD-Mice Are Protected from Diabetes by Restoring the Balance of Regulatory to Effector-T-Cells. Azzi J, Thueson L, Moore R, Abdoli R, Reijonen H, Abdi R. PLoS One 12 e0169695 (2017)
  314. Periploca forrestii saponin ameliorates CIA via suppressing proinflammatory cytokines and nuclear factor kappa-B pathways. Bao C, Liu Y, Sun X, Xing C, Zeng L, Sun G. PLoS One 12 e0176672 (2017)
  315. Phosphoinositide 3-kinase inhibitor AS605240 ameliorates streptozotocin-induced Alzheimer's disease like sporadic dementia in experimental rats. Alluri R, Ambati SR, Routhu K, Kopalli SR, Koppula S. EXCLI J 19 71-85 (2020)
  316. Plasma Hsp90 Level as a Marker of Early Acute Lymphoblastic Leukemia Engraftment and Progression in Mice. Milani M, Laranjeira AB, de Vasconcellos JF, Brandalise SR, Nowill AE, Yunes JA. PLoS One 10 e0129298 (2015)
  317. Reduction in Renal Ischemia-Reperfusion Injury in Mice by a Phosphoinositide 3-Kinase p110gamma-Specific Inhibitor. Kim N, Woo DC, Joo SJ, Song Y, Lee JJ, Woo CW, Kim ST, Hong S, Cho YM, Han DJ. Transplantation 99 2070-2076 (2015)
  318. Repurposing of Pirfenidone (Anti-Pulmonary Fibrosis Drug) for Treatment of Rheumatoid Arthritis. Gan D, Cheng W, Ke L, Sun AR, Jia Q, Chen J, Lin J, Li J, Xu Z, Zhang P. Front Pharmacol 12 631891 (2021)
  319. Rheumatoid Arthritis Fibroblast-like Synoviocyte Suppression Mediated by PTEN Involves Survivin Gene Silencing. Chen D, Liu D, Liu D, He M, Peng A, Xu J, Lin L, Luo F, Chen L, Huang X, Zhuang J, Xu J. Sci Rep 7 367 (2017)
  320. Congress 10th anniversary Inflammation and Immune Diseases Drug Discovery and Development Summit. 20-21 March 2006, New Brunswick, USA. Braddock M, Murray C. Expert Opin Investig Drugs 15 721-727 (2006)
  321. 8e Protects against Acute Cerebral Ischemia by Inhibition of PI3Kγ-Mediated Superoxide Generation in Microglia. Wang L, Wang X, Li T, Zhang Y, Ji H. Molecules 23 E2828 (2018)
  322. Differential Effects of Inhibitor Combinations on Lysophosphatidic Acid-Mediated Chemokine Secretion in Unprimed and Tumor Necrosis Factor-α-Primed Synovial Fibroblasts. Hui W, Zhao C, Bourgoin SG. Front Pharmacol 8 848 (2017)
  323. Intraarticular gene transfer of SPRY2 suppresses adjuvant-induced arthritis in rats. Zhang W, Zhu J, Du Z, Yu J, Xu Y, Wang F. Appl Microbiol Biotechnol 99 6727-6735 (2015)
  324. PI3Kγ deletion reduces variability in the in vivo osteolytic response induced by orthopaedic wear particles. Greenfield EM, Tatro JM, Smith MV, Schnaser EA, Wu D. J Orthop Res 29 1649-1653 (2011)
  325. Topical Application of the PI3Kβ-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita. Zillikens H, Kasprick A, Osterloh C, Gross N, Radziewitz M, Hass C, Hartmann V, Behnen-Härer M, Ernst N, Boch K, Vidarsson G, Visser R, Laskay T, Yu X, Petersen F, Ludwig RJ, Bieber K. Front Med (Lausanne) 8 713312 (2021)
  326. p84 forms a negative regulatory complex with p110γ to control PI3Kγ signalling during cell migration. Turvey ME, Klingler-Hoffmann M, Hoffmann P, McColl SR. Immunol Cell Biol 93 735-743 (2015)
  327. Comparative proteomic analysis implicates eEF2 as a novel target of PI3Kγ in the MDA-MB-231 metastatic breast cancer cell line. Niu M, Klingler-Hoffmann M, Brazzatti JA, Forbes B, Akekawatchai C, Hoffmann P, McColl SR. Proteome Sci 11 4 (2013)
  328. Development of an Ultra High Resolution PET Scanner for Imaging Rodent Paws: PawPET. Godinez F, Gong K, Zhou J, Judenhofer MS, Chaudhari AJ, Badawi RD. IEEE Trans Radiat Plasma Med Sci 2 7-16 (2018)
  329. Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors. Terstiege I, Perry M, Petersen J, Tyrchan C, Svensson T, Lindmark H, Öster L. Bioorg Med Chem Lett 27 679-687 (2017)
  330. Loss of phosphoinositide 3-kinase P110γ is protective in the acute phase but detrimental in the resolution phase of hapten-induced colitis. Prescott D, Atkinson B, Döring A, Brown S, Petri B, McKay DM, Waterhouse CC. Inflamm Bowel Dis 19 489-500 (2013)
  331. Meisoindigo, but not its core chemical structure indirubin, inhibits zebrafish interstitial leukocyte chemotactic migration. Ye B, Xiong X, Deng X, Gu L, Wang Q, Zeng Z, Gao X, Gao Q, Wang Y. Pharm Biol 55 673-679 (2017)
  332. Molecular basis for differential activation of p101 and p84 complexes of PI3Kγ by Ras and GPCRs. Rathinaswamy MK, Jenkins ML, Duewell BR, Zhang X, Harris NJ, Evans JT, Stariha JTB, Dalwadi U, Fleming KD, Ranga-Prasad H, Yip CK, Williams RL, Hansen SD, Burke JE. Cell Rep 42 112172 (2023)
  333. Meta-Analysis Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials. Wang Z, Zhou H, Xu J, Wang J, Niu T. Front Immunol 13 1070660 (2022)
  334. Screening of a Panel of Low Molecular Weight Compounds That Inhibit Synovial Fibroblast Invasion in Rheumatoid Arthritis. Sugiura T, Kamino H, Nariai Y, Murakawa Y, Kondo M, Kawakami M, Ikeda N, Uchio Y, Urano T. J Immunol 205 3277-3290 (2020)
  335. Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2. Mariano M, Hartmann RW, Engel M. Eur J Med Chem 112 209-216 (2016)
  336. A novel cytokine consisting of the p40 and EBI3 subunits suppresses experimental autoimmune arthritis via reciprocal regulation of Th17 and Treg cells. Lee SY, Moon SJ, Moon YM, Seo HB, Ryu JG, Lee AR, Lee CR, Kim DS, Her YM, Choi JW, Kwok SK, Park SH, Cho ML. Cell Mol Immunol 19 79-91 (2022)
  337. Discovery of a Novel Series of Potent and Selective Alkynylthiazole-Derived PI3Kγ Inhibitors. Bandarage UK, Aronov AM, Cao J, Come JH, Cottrell KM, Davies RJ, Giroux S, Jacobs M, Mahajan S, Messersmith D, Moody CS, Swett R, Xu J. ACS Med Chem Lett 12 129-135 (2021)
  338. Hyaluronic Acid Hydrogels Hybridized With Au-Triptolide Nanoparticles for Intraarticular Targeted Multi-Therapy of Rheumatoid Arthritis. Li C, Liu R, Song Y, Chen Y, Zhu D, Yu L, Huang Q, Zhang Z, Xue Z, Hua Z, Lu C, Lu A, Liu Y. Front Pharmacol 13 849101 (2022)
  339. Hydrophobic Bile Salts Induce Pro-Fibrogenic Proliferation of Hepatic Stellate Cells through PI3K p110 Alpha Signaling. Zimny S, Koob D, Li J, Wimmer R, Schiergens T, Nagel J, Reiter FP, Denk G, Hohenester S. Cells 11 2344 (2022)
  340. Novel PI3Kγ mutation in a 44-year-old man with chronic infections and chronic pelvic pain. Bojarski EF, Strauss AC, Fagin AP, Plantinga TS, Hoischen A, Veltman J, Allsop SA, Granadillo VJ, William A, Netea MG, Dimitrakoff J. PLoS One 8 e68118 (2013)
  341. PBT-6, a Novel PI3KC2γ Inhibitor in Rheumatoid Arthritis. Kim J, Jung KH, Yoo J, Park JH, Yan HH, Fang Z, Lim JH, Kwon SR, Kim MK, Park HJ, Hong SS. Biomol Ther (Seoul) 28 172-183 (2020)
  342. Reduced Mrp2 surface availability as PI3Kγ-mediated hepatocytic dysfunction reflecting a hallmark of cholestasis in sepsis. Beer AJ, Hertz D, Seemann E, Beretta M, Westermann M, Bauer R, Bauer M, Kessels MM, Qualmann B. Sci Rep 10 13110 (2020)
  343. Synthesis and Pharmacological Evaluation of 4-Iminothiazolidinones for Inhibition of PI3 Kinase. Pinson JA, Schmidt-Kittler O, Frazzetto M, Zheng Z, Jennings IG, Kinzler KW, Vogelstein B, Chalmers DK, Thompson PE. Aust J Chem 65 1396-1404 (2012)
  344. Synthesis of a 6-Aza-Isoindolinone-Based Inhibitor of Phosphoinositide 3-Kinase γ via Ruthenium-Catalyzed [2 + 2 + 2] Cyclotrimerization. Collier PN, Panchagnula A, O'Dowd H, Le Tiran A, Aronov AM. ACS Med Chem Lett 10 117-120 (2019)
  345. A PI3Kγ signal regulates macrophage recruitment to injured tissue for regenerative cell survival. Zhou S, Liu Z, Kawakami A. Dev Growth Differ 64 433-445 (2022)
  346. A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Cho S, Jang E, Yoon T, Hwang H, Youn J. Clin Exp Immunol 211 31-45 (2023)
  347. Actuation of single downstream nodes in growth factor network steers immune cell migration. Pal DS, Banerjee T, Lin Y, de Trogoff F, Borleis J, Iglesias PA, Devreotes PN. Dev Cell 58 1170-1188.e7 (2023)
  348. Allosteric activation or inhibition of PI3Kγ mediated through conformational changes in the p110γ helical domain. Harris NJ, Jenkins ML, Nam SE, Rathinaswamy MK, Parson MAH, Ranga-Prasad H, Dalwadi U, Moeller BE, Sheeky E, Hansen SD, Yip CK, Burke JE. Elife 12 RP88058 (2023)
  349. Distinct functional and conformational states of the human lymphoid tyrosine phosphatase catalytic domain can be targeted by choice of the inhibitor chemotype. Vidović D, Xie Y, Rinderspacher A, Deng SX, Landry DW, Chung C, Smith DH, Tautz L, Schürer SC. J Comput Aided Mol Des 25 873-883 (2011)
  350. Phosphoinositide 3-kinase δ/γ inhibition does not prevent concanavalin A-induced hepatitis. Liu Y, Xiong L, Chang Y, Tang J, Ang W, Yang T, Pi W, Yang X, Ye W, Luo Y, Wang Z. Mol Med Rep 8 1305-1310 (2013)
  351. Phosphoinositide 3-kinase-gamma as a target in rheumatoid arthritis and systemic lupus. Doggrell SA. Expert Opin Ther Targets 10 627-630 (2006)
  352. Ratiometric Reactive Oxygen Species Nanoprobe for Noninvasive In Vivo Imaging of Subcutaneous Inflammation/Infection. Zhou J, Weng H, Huang Y, Gu Y, Tang L, Hu W. J Biomed Nanotechnol 12 1679-1687 (2016)
  353. Listeria InlB Expedites Vacuole Escape and Intracellular Proliferation by Promoting Rab7 Recruitment via Vps34. Cain RJ, Scortti M, Monzó HJ, Vázquez-Boland JA. mBio 14 e0322122 (2023)
  354. AS-605240 Blunts Osteoporosis by Inhibition of Bone Resorption. Sun J, Cai G, Shen J, Cheng P, Zhang J, Jiang D, Xu X, Lu F, Chen L, Chen H. Drug Des Devel Ther 17 1275-1288 (2023)
  355. BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells. Kong W, Sender S, Taher L, Villa-Perez S, Ma Y, Sekora A, Ruetgen BC, Brenig B, Beck J, Schuetz E, Junghanss C, Nolte I, Murua Escobar H. Int J Mol Sci 22 12673 (2021)
  356. Control of CD4+ T Cell Differentiation and Function by PI3K Isoforms. Cameron B, Zaheer SA, Dominguez-Villar M. Curr Top Microbiol Immunol 436 197-216 (2022)
  357. Deciphering the role of TNF‑α‑induced protein 8‑like 2 in the pathogenesis of necrotizing enterocolitis in neonatal rats. Luo J, Yu S, Xu J, Sun X, Wang R. Exp Ther Med 26 443 (2023)
  358. Exploration of the mechanism by which Huangqi Guizhi Wuwu decoction inhibits Lps-induced inflammation by regulating macrophage polarization based on network pharmacology. Wang S, Ji T, Wang L, Qu Y, Wang X, Wang W, Lv M, Wang Y, Li X, Jiang P. BMC Complement Med Ther 23 8 (2023)
  359. GCSB-5 regulates inflammatory arthritis and pain by modulating the mitogen-activated protein kinase signaling pathway in a murine model of rheumatoid arthritis. Bang J, Kim G, Young Park S, Jung HR, Kim SH, Kim JM. Arch Rheumatol 38 566-578 (2023)
  360. Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor. Cai Y, Yu J, Ren P, He J, Wu Z, Xiao K, Jia H, Wang J, Sai Y, Dai G, Li X, Su W, Ngo K, Castro G, Acton PD, Fung-Leung WP, Edwards JP, Venable J, Rao TS. Pharmacol Res Perspect 8 e00559 (2020)
  361. Mannan-Binding Lectin Deficiency Limits Inflammation-induced Myeloid-Derived Suppressor Cells Expansion via Modulating Tumor Necrosis Factor Alpha-triggered Apoptosis. Dong L, Jiang H, Chen K, Xie J, An Q, Deng F, Sun Z, Liu Y, Zhou J, Zhang L, Lu X, Wang M, Chen Z, Zou X, Zuo D. Int J Biol Sci 18 1580-1593 (2022)
  362. Pathological pathway analysis in an experimental rheumatoid arthritis model and the tissue repair effect of acupuncture at ST36. Zhang Y, Wang H, Gong YN, Yang FM, Wang SJ, Liu YY, Gui YQ, Xie F, Xu ZF, Guo Y. Front Immunol 14 1164157 (2023)
  363. STX0119 ameliorates arthritis in SKG mice via inhibiting T helper 17. Hayat F, Lee SH, Lee EJ, Kim SJ, Jung K, Lee SK, Youn J, Min JK, Cho ML, Shin DY. Tissue Eng Regen Med 13 91-99 (2016)
  364. Tau deficiency inhibits classically activated macrophage polarization and protects against collagen-induced arthritis in mice. Chen M, Fu W, Xu H, Liu CJ. Arthritis Res Ther 25 146 (2023)
  365. Therapeutic Effect of Costunolide in Autoimmune Hepatitis: Network Pharmacology and Experimental Validation. Huang Z, Nie S, Wang S, Wang H, Gong J, Yan W, Tian D, Liu M. Pharmaceuticals (Basel) 16 316 (2023)
  366. Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway. Di X, Pan Y, Yan J, Liu J, Wen D, Jiang H, Zhang S. Heliyon 10 e23165 (2024)
  367. Comparative Study [Biological therapies: evolution or revolution?]. Sibilia J. Presse Med 35 637-640 (2006)
  368. [Not Available]. Pablos Álvarez JL. Reumatol Clin 2 Suppl 2 S9-S12 (2006)


Quick links